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INTRODUCTION 
    In Siddha system of medicine the diseases are classified into three major categories 
that is Vatham, Pitham, and Kabam diseases. Siddha system is broadly classified into 4448 
diseases which Yugimuni says to vatha diseases are 80 in number. In which “Uthira vadha 
Suronitham” is one among them and the signs and symptoms of this disease can be  
correlated with Rheumatoid Arthritis (R.A) in Modern science. 
In Siddha system of medicine many formulations have been indicated for challenging 
and chronic diseases like Cancer, Brain tumours, Blood cancer, Cardiac diseases,Rheumatoid 
Arthritis, Oesteo Arthritis. (Ref: http//www.sysindia. .com/medical/about siddha.html) 
          Rheumatoid Arthritis (RA) is the most common persistent inflammatory arthritis, 
occurring throughout the world and in all ethnic groups. The clinical course is prolonged, 
with intermittent exacerbations and remissions.           
About 1% of the world's population is affected by rheumatoid arthritis, women three 
times more often than men. The incidence of RA is of 3 cases per 10,000 population per 
annum. Onset is uncommon under the age of 15 and from then on the incidence rises with age 
until the age of 80.[Reference: Davidson’s Principle and Practice of Medicine, pg no:1088]. 
            In India the prevalence of this disease affecting 0.75% of population. Projected to the 
whole population, this would give a total of about seven million patients. The prevalence of 
RA in India is quite similar to that reported from the developed countries. (Ref: Prevalence of 
Rheumatoid Arthritis in adult Indian population, Department of medicine, AIMS, New 
Delhi). 
          Around 40% of RA patients are registered disabled within 3 years; around 80% are 
moderately to severely disabled within 20 years and 25% will require a large joint 
replacement.(Reference: Davidson’s Principle and Practice of Medicine, pg no:1088). 
           Many siddha formulations available to treat Uthira vatha suronitham in Siddha system. 
So, Author chosen this siddha preparation after elaborated search and it is aimed to  reducing 
not only the pain but also the restricted movements and other symptoms of this disease Uthira 
vatha suronitham. Here, the  author have chosen the drug   “Amirtharasa Maathirai” (Ref: 
Agasthiyar Mani 4000 ennum Vaithiya Chinthamani   Venbaa 4000 second part) as Internal 
Medicine  and Suronitha Vatha Ennai (Ref: Theraiyar Vagadam ) as External Medicine. 
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AIM AND OBJECTIVES 
 
PRIMARY OBJECTIVE:   
To Evaluate the Safety and Therapeutic efficacy of “Amirtharasa Mathirai” 
(Internal) and “Suronitha Vatha Ennai” (External) in reducing the pain and restricted joint 
movements in the treatment of “Uthira Vatha Suronitham (Rheumatoid Arthritis).” 
 
 
SECONDARY OBJECTIVES: 
1. To screen the elements present and the particle size of the elements in the trial drug. 
2. To evaluate the safety of trial drugs by doing Acute toxicity studies in animal models. 
3. To access the predominance of the disease related to Age, Sex, Socio-economic status, 
Habits, Family history etc., 
4. To correlate the etiology, clinical features, signs and symptoms of Uthiravatha 
Suronitham in Siddha system to Rheumatoid Arthritis in Modern science. 
5. To access the Siddha basic principles like Envagai thervu, Neerkkuri and Neikkuri   
pattern in Uthira Vatha Suronitham patients.   
6. To access the effect of Varmam in Uthira vatha Suronitham patients. 
7. To find out whether there are any  side effects/ adverse effects produced by the trial 
drug Amirtharasa Mathirai (Internal) during treatment. 
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REVIEW OF LITERATURE 
SIDDHA ASPECTS 
UTHIRAVATHA SURONITHAM 
Siddha system  of Medicine is an ancient one with spiritual  and qualities. The sources 
of Siddha medicines include Herbs, Minerals, Metals and also Living kingdoms. 
Siddha system was propounded by the siddhars is a vast and unique system which 
defines health as a perfect state of physical, psychosocial, social and spiritual well being of an 
individual. 
  The system not only deals with medicinal but with spirituality,  righteous way of 
living, Rejuvenation and its main aim is attainment of perfection. 
“«ñ¼ò¾¢ÖûÇ§¾ À¢ñ¼õ 
À¢ñ¼ò¾¢ÖûÇ§¾ «ñ¼õ.” 
- ºð¼ ÓÉ¢ »¡Éõ. 
 The universe around as in the Macrocosm (Andam) and the human body is considered 
as the Microcosm (Pindam). Any changes in the Macrocosm will have its impact in the 
Microcosm in the human body. 
“¿¢Äó¾£ ¿£÷ÅÇ¢ Å¢Íõ§À¡ ¨¼óÐõ 
¸Äó¾ ÁÂì¸õ ¯Ä¸õ ¬¾Ä¢ý 
þÕ¾¢¨½ ³õÀ¡ø þÂ¦ÉÈ¢ ÅÆ¡ «¨Áò 
¾¢Ã¢Å¢ø ¦º¡ø¦Ä¡Î ¾Æ¡«ø §ÅñÎõ.” 
    -¦¾¡ø¸¡ôÀ¢Âõ ¦À¡Õû «¸Ã¡¾¢. 
The poet explains that both Andam and Pindam formed by the basic five elements 
called pancha boodhams. They are 
 1. Pirithivi (Earth) 
 2. Appu (Water) 
 3. Theyu (Fire) 
 4. Vaayu (Air) 
 5. Aahayam (Ether) 
These five elements combined to form Three Thathus. 
 1. Vatham 
 2. Pitham 
 3. Kabam 
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These Three Thathu  composed of  
1. Vatham  = Kattru + Aahayam 
2. Pitham   = Theyu 
3. Kabam   = Prithivi + Appu 
The physiological units of the Human body is otherwise called as Vali (Vatham), 
Azhal (Pitham) and Iyyam (Kabam). They are also formed by the combination of the five 
basic elements. Accordingly Vali is formed by the combination of Vayu (Air) and Aagayam 
(Space). This is the Creative force. Azhal is formed by theyu (Fire). This is the Force of 
Preservation. Iyyam is formed by Prithivi (Earth) and Appu (Water). This is the Force of 
Protection. These three humors are in the ratio of 4:2:1 in equilibrium which is a healthy 
normal condition and disturbance in their equilibrium leads to diseases. This is denoted in 
                  "¦À¡í¸¢Â ¨¾óÐìÌû ¦À¡øÄ¡¾Ð þõ ãýÚ¾¡ý 
  ¾í¸¢Â Å¡Ô ºÁò¾ý Á¸¡Å¡¾õ 
    Àí¸¢Â ÅýÉ¢Â¡ø ÀÌó¾Ð À¢ò¾§Á 
   ÀÌó¾ ºÄò¾¢ø ÀÃ¢º¢ìÌõ ¿ø¨ÄÔõ 
   ÅÌó¾ þõãýÈ¡ø ÅÇ÷ó¾Ð §¿¡¦ÂøÄ¡õ 
    «Ìó¾Ð ¾¡ÉÈ¢óÐ «ÇÅ¢ð¼ §Â¡¸¢¸û 
   Á¸¢úó§¾ Â¢¾¢ø ¿¢ýÈ ÁÂì¸õ «È¢Å¡§È." 
                                                                               -À¾¢¦½ý º¢ò¾÷ ¿¡Ê º¡Š¾¢Ãõ 
These three Thathus Perceived as Naadi which is unique feature of Siddha system. 
When the above three humours are affected (or) not in a balanced state ,they become Kuttram 
which predisposes to diseases. 
I. Vali (Vatham) 
These active elements are always supported by the two stable elements, for change 
can only happen upon the foundation of stable. Thus Vayu and Aahaayam combine to 
become “Vatha humor” which controls all aspects of movements as well as space with in 
the body. In spite of this combination, however, Vatham sends to primarily display the 
characteristics of Vayu-Air. The words “Dry, Light, Cold, Quick, Rough, Minute and 
Mobile” describes the characteristics of  Vatham. 
II. Azhal (Pitham) 
This is the function that governs all the body’s conversion processes as well as its heat 
and energy producing capacities. Pitham is primarily characterized by the qualities of Theyu, 
which are “hot, sharp, penetrating, light, acidic, and slightly oily”. 
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III. Iyyam (Kapam): 
It controls liquefaction, lubrication and cohesion. It is also responsible for giving 
solidity and structure to the body. Kabam primarily reflects the qualities of the water, but also 
some traits of the earth elements, consequently, Kabam is heavy, slow, cold, steady, solid and 
oily. 
        ARTHRITIS – MOOTTU VALI 
Arthritis is a group of conditions involving damage to the joint of the body. There are 
over 100 different forms of arthritis. Excess of vatham affects the joints all over the body and 
Vitiation of Kabam causes indigestion. Thus the end product of digestion associated with 
vatham, pitham, kabam blocks the tissue pores and passages with waxy material. It also 
affects simultaneously the joints of the body such as knee, shoulder, hip, neck etc. This 
produces the stiffness of the joints. Hence it is also known as Mudakku vatham.  
       UTHIRAVATHA SURONITHAM  
Definition (Iyal) 
 
Uthiravatha  Suronitham  is  a  type  of  Arthritis  characterised  by  pain,  swelling,  
pricking sensation, stiffness of the joints  and restriction of movements due to deranged 
vatham and pitham.  
Uthiravatha Suronitham = Uthiravatham + Suronitham 
Uthiravatham                   = Arthritis of rheumatic origin marked by severe  
pain and the formation of inflammatory nodules in the 
region of joints especially in the limbs of the body.  
Suronitham           = Blood and menstrual blood. 
a) According to T.V.Sambasivam Pillai. 
Suronitham is a disorder of menstruation in women characterized by affection in chest 
and limbs, extreme sensibility to pain, dryness in the skin, pain in nerves accompanied by 
intense bodily pain. 
 AETIOLOGY  (§¿¡ö ÅÕõ ÅÆ¢)  
1. According to Yugi Vaithya Sinthamani,                                         
"±ýÉ§Å Å¡¾ó¾¡ ¦ÉñÀ ¾¡Ìõ 
         Á¢Ìò¾¢§Ä ÁÉ¢¾÷¸Ùì ¦¸öÐ Á¡Ú 
 À¢ýÉ§Å ¦À¡ó¾¨É§Â §º¡Ãï ¦ºöÐ 
        ¦ÀÃ¢§Â¡÷¸û À¢Ã¡Á½¨Ãò à‰ ½¢òÐõ 
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ÅýÉ§Å Åî¦º¡ò¾¢ü §º¡Ãï ¦ºöÐ 
          Á¡¾¡À¢¾¡ ÌÕ¨Å ÁÈó¾ §À÷ìÌõ  
¸ýÉ§Å §Å¾ò¨¾ ¿¢ó¨¾¦ºö¾ §À÷ìÌí 
          ¸¡Âò¾¢ü ¸Äó¾¢Î§Á Å¡¾ó ¾¡§É.” 
"¾¡¦ÉýÈ ¸ºô§À¡Î ÐÅ÷ôÒ ¨ÃôÒ 
          º¡¾¸Á¡ö Á¢ïÍ¸¢Ûï º¨Áò¾ ÅýÉõ 
   ¬¦ÉýÈ Å¡È¢ÉÐ ¦À¡º¢ò¾ Ä¡Öõ 
          ¬¸¡ò §¾ÈÄÐ ÌÊò¾ Ä¡Öõ 
     À¡¦ÉýÈ À¸ÖÈì¸ Á¢Ã¡Å¢ Æ¢ôÒ 
          ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã ¦Áö¾ø 
     §¾¦ÉýÈ ¦Á¡Æ¢Â¡ü §Áü º¢ó¨¾ Â¡¸¢ø 
          º£ì¸¢ÃÁ¡ö Å¡¾ÁÐ ¦ºÉ¢ìÌó ¾¡§É." 
"¬½¡É ÅÃýÈ¦Éª§Â Á¾¢Â¡ Á¡ó¾÷ 
             «¸¾¢ÀÃ §¾º¢Â÷¸ð ¸ýÉ Á£Â¡÷ 
        §¸¡É¡É ÌÃ¦Á¡Æ¢¨Â ÁÈó¾ §À÷¸û 
             ¦¸¡¨Ä¸Ç× ¦À¡ö¸¡Áí ÌÈ¢ò¾ §À÷ìÌ 
        °É¡É º¼ó¾ýÉ¢ø Å¡¾õ ÅóÐ 
             ¯üÀÅ¢ìÌõ §Å¾ò¾¢ Öñ¨Á ¾¡§É." 
- ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
According to the saint Yugi’s text, those who are squandering money, insulting the 
elders, blaspheming the Holy books, not respecting the divine gifts, abandoning or forgetting 
the parents having wickedness in their mind and those with sleeping in the day time and 
awake up during night will get Vali diseases, hot taste, increased intake of water, excessive 
starvation, Increased intake of bitter and astringent taste, increased sexual indulgence desire 
will produce Vali diseases. 
FACTORS THAT INFLUENCE THE VATHA TYPE OF DISEASES: 
¸¡Ä þÂøÒ – Environmental Factors: 
Relation between occurrence of Vatha Diseases and Paruva Kaalam: 
                “¬ÊÂ¡¾¢Â¡ö ³ôÀº¢ ®È¡ö 
                 «É¢ÄÁ¾ü §¸¡ÃÃº¢Âø ¸¡Äõ.” 
Vatham elevates in the body from the month of Aadi to Iyppasi i,e from the middle of 
Muthuvenil kaalam, Karkaalam to half of Koothir kaalam. 
 To summarise, Vatha diseases occur due to certain diet capable of increasing vatham, 
certain habits and environmental changes which elevates vatham. 
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Diet 
    "¦¾¡Æ¢ø¦ÀÚ ¨¸ôÒì¸¡÷ò¾ø ÐÅ÷ò¾ø Å¢ïÍ¸¢Ûï 
  §º¡Õõ ¸¨ÆÂ¾¡õ ÅÃÌ Áü¨Èô¨Àó¾¢¨É ÂÕó¾¢É¡Öõ 
   ±Æ¢ø ¦ÀÈô À¸ÖÈí¸¢ þÃÅ¢É¢ÖÈí ¸¡¾¾¡Öõ 
   Á¨Æ ¿¢¸÷ ÌÆÄ¢É¡§Ä Å¡¾í§¸¡ À¢ìÌí ¸¡§½." 
                                               -   ÀÃÃ¡º §º¸Ãõ 
According to Pararasa Sekeram, excess consumption  of bitter taste, astringents and 
sour tastes, increased intake of old cooked rice, intake of grains, persons who are sleeps in the 
day time and wake up at night time will  get Vatham diaeases. 
CLINICAL FEATURES OF UTHIRAVATHA SURONITHAM: 
“¨Å¸¢¾Á¡öì ¸¨½ì¸¡Ö ÓÆí¸¡ø ¾¡Ûõ 
   Áü¸¼ì ºóÐ ÒÈÅÊÔõ Å£í¸¢î 
¦ºö¸¢¾ Á¡ü º¢ÚÅ¢Ãø¸û Á¢¸×õ ¦¿¡óÐ 
   º¢ó¨¾ ¾ÎÁ¡È¢§Â ºÄ¢ôÒñ¼¡Ìõ 
¨À¸¢¾Á¡õ ÀÂ¢ò¾¢Âò ¾¢øÄ¡¾ Á¢ïº¢ô 
   À¡ÃÁ¡ö ¯üÀÅ¢òÐ «ÆÖñ¼¡Ìõ 
¯ö¸¢¾Á¡õ «ºÉÁÐ ¾¡Ûõ §Åñ¼¡ 
  ¯¾¢Ã Å¡¾ Í§Ã¡Ã¢½¢¾ò¾¢ Û½÷îº¢Â¡§Á.” 
                                 -ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
   It is characterised by pain and swelling in both ankle joints, knee joints and all smaller 
joints of the hands, feeling of tiredness, fever, loss of appetite and mental depression. 
         Also the term ‘Markadam’ (Áü¸¼õ) indicates the hand of monkey (T.V.Sampasivam 
Pillai dictionary Pg no: 753) anatomically which can be correlated clinically with Swan neck 
deformity and wasting of thenar muscle in Rheumatoid Arthritis.   
2. THE CLINICAL FEATURES OF UTHIRAVATHA SURONITHAM IN ‘PARA 
RASA SEKARAM’: 
“Àì¸Óõ Á¡÷Òõ Ü¼ôÀüÈ¢§Â þØòÐì ¦¸¡ñÎ 
¦¿ì¸¢§Â Á¡÷À¢¨ÇòÐ §¾¡¾¡ö ¿ÃõÀ¢ØòÐ 
´ì¸§Å ºÂ¢ò¾¢Âí¸û ¯Â÷óÐ¼ý §ÁÖõ ¸¡Äõ 
Á¢ìÌ§Á ¯¾¢ÃÅ¡¾õ ±ýÈ¢Ð Å¢ÇõÀÄ¡§Á.” 
                     -   ÀÃÃ¡º §º¸Ãõ 
It is characterised by pain and tenderness of the axilla, breathlesness, pain in the upper 
limbs and the lower limbs. 
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§¿¡öì¸½¢ôÒ ( DIAGNOSIS) 
"§¿¡ö¿¡Ê §¿¡öÓ¾ É¡Ê ÂÐ¾½¢ìÌõ 
  Å¡ö¿¡Ê Å¡öôÀî ¦ºÂø." 
                                     -¾¢ÕìÌÈû. 
 This Thirukural quote explains the importance of diagnosis as it is to be made in order 
of the aetiology, root of cause of the disease thereby treating the disease with appropriate 
medicine.  
 Piniyari muraigal (Method of Diagnosis) 
             Piniyari muraigal (Method of Diagnosis) is based upon the three main principles: 
· Poriyal Arithal (Inspection) 
· Pulanal Arithal (Palpation) 
· Vinaathal (Interrogation) 
Poriyalarithal (Inspection): 
“Poriyalarithal” means examining the “Pori” of the patient by the physician for proper 
diagnosis. 
 Pori - five sense organs. 
 They are as follows, 
· Nose  
·  Tongue  
·  Eye  
·  Skin   
·  Ear. 
2. Pulanalarithal (Palpation): 
“Pulanal arithal” means examining the “Pulan” of the patient by the physician to 
diagnosis a disease. 
  Pulan -  senses  
  They are, 
· Smell 
· Taste 
· Vision 
· Sensation of touch 
· Hearing 
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3. Vinaathal (Interrogation): 
Vinaathal is gathering of information about the history of the disease, its clinical 
features etc., from the patient or his close relatives who are taking care of them. Vinaathal is 
helpful when the patient is not in a position to speak or when the patient is child. 
Types of Naadi (Pulse) felt in Uthiravadha Suronitham: 
  In Siddha system of Medicine “Naadi diagnosis (Pulse reading)” is the first and 
foremost diagnostic parameter. 
 In Uthiravadha Suronitham the following types of Naadi can be commonly seen. 
They are,  
· Vadhapitham 
· Vadhakabam 
· Pithavadham 
· Kabavatham 
DIFFERENTIAL DIAGNOSIS 
Uthiravatha Suronitham is differentiated from other types of Vatha Suronitham as 
follows: 
S.NO DISEASES SIGNS AND SYMPTOMS 
 Uthiravatha 
Suronitham 
§ Swelling of ankle joints, hip joints, 
and knee joints. 
§ Pain and tenderness of minor joints 
especially phalanges. 
§ Depression. 
§ Loss of appetite. 
§ Increased Vatha and Pitham. 
1. Vatha Suronitham § Emaciation. 
§ Swelling of joints. 
§ Restricted movements. 
§ Joint pain. 
§ Discomfort. 
§ Excessive salivation. 
§ Loss of appetite. 
2. Sithuvatha Suronitham § Anasarca. 
§ Wrinkles. 
§ Neural pain. 
§ Glossy tongue. 
§ Sialorrhoea. 
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§ Bullous eruption as in burn. 
§ Exfoliation,swelling  and 
Warmthness. 
3. Vaikitha Vatha 
Suronitham 
§ Swelling with hyperaemia. 
§ Soft on touch. 
§ Cough with pyrexia. 
§ Irritability. 
4. Paithiya Vatha 
Suronitham 
§ Hyperaemia. 
§ Tenderness in knee, elbow and 
smaller joints. 
§ Poly arthralgia. 
§ Pyrexia. 
§ Anaemia. 
5. Slethumavatha 
Suronitham 
§ Chillness with abdominal distension. 
§ Severe pain and Head ache. 
§ Syncope and Hallucination. 
§ Dryness of mouth and Anorexia. 
§ Tachycardia. 
6. Utharavatha Suronitham § Fever with rigor. 
§ Dryness of mouth. 
§ Pain in all over the joints. 
§ Headache. 
§ Diarrhoea. 
§ Excessive thirst. 
§ Hunger. 
 
             LINE OF TREATMENT 
In Siddha system, the treatment is based upon the Mukkutram principle. Treatment is 
not only for perfect healing but also for the Prevention of disease progression and 
Rejuvenation of Udal kattugal. 
While treating a disease, it is essential to know the etiology, the nature of the patient, 
severity of the illness, the seasons and the time of occurrence.  
Line of treatment is as follows: 
Kappu (Prevention) 
Neekkam (Treatment) 
Niraivu (Restoration)  
I.KAAPPU (PREVENTION): 
“Prevention is better than cure” is a proverb. Knowing the cause there by removing 
it and thus preventing the disease is the main aim of Siddha system of medicine. 
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Siddha system emphasizes the purification of thought and activities in the underlying 
lines quoted from the text “Theraiyar Pinianuga Vithi” which emphasizes virtueness to be 
followed even in the daily life activities.i.e., 
À¡Öñ§À¡õ ±ñ¦½ö¦ÀÈ¢ý ¦Åó¿£÷ ÌÇ¢ô§À¡õ 
 À¸üÒ½§Ã¡õ; À¸üÚÂ¢ø§Å¡õ: À¡§Â¡¾ÃÓ ãò¾ 
 ²Äï§º÷ ÌÆÄ¢Â§Ã¡ ÊÇ¦ÅÂ¢Öõ Å¢Õõ§À¡õ; 
 þÃñ¼¼ì§¸¡õ; ´ý¨ÃÅ¢§¼¡õ;  þ¼Ð¨¸Â¢ü ÀÎô§À¡õ; 
2.NEEKAM (TREATMENT IN SIDDHA): 
The aim of treatment is based on, 
a) To bring the Three Thodams to normal equilibrium state. 
b) To treat the patient by Internal and external medicines. 
c) To stabilize 7 Udal thadhukal and 3 Uyir thadhukal. 
To bring the three Thodams to normal equilibrium state first by giving purgation. 
Purgation drug: 
 Purgation with Agasthiyar Kuzhambu – 1 Kundri(130 mgs) o.d early morning 
with Ginger juice will be given for balancing the deranged mukkutram on the first day of the 
treatment.  
Internal Drug:  
Amirtharasa Mathirai  - 1 Kundri(130 mgs)  (twice a day) with water 
External Drug: 
Suronitha Vatha Ennai  - External application over the affected joints. 
Diet Restrictions (Pathiyam): 
During the course of treatment, the patients were advised to follow certain diet 
restrictions (Icha pathiyam) which is mentioned for vatha diseases. 
1. Kadugu (Mustar seed) 
2. Ell Nei (Gingelly oil) 
3. Kalyana Poosanikkai 
4. Kadalai 
5. Thengai 
6. Mangai 
7. Poondu 
8. Pala 
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9. Kollu 
10. Pugaiyilai 
11. Pagal 
          12. Agathi 
13. Sour taste 
14. Astringent taste  
3. NIRAIVU (RESTORATION): 
Reassurance from disease recovery was given to all patients by promoting the 
awareness about the dietary, seasonal, emotional influence on the disease. Life-style 
modification was also advised to them. 
YOGAM FOR UTHIRAVATHA SURONITHAM: 
The patients are advised to do the following Yogasanas regularly. 
· Poorna santhi asanam 
· Mathriga pranayamam 
In case of sleep disturbances and depression: 
Nithirai pranayamam and Dhiyanam. 
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     MODERN ASPECTS 
 
Rheumatoid Arthritis 
 
An Introduction: 
Rheumatoid Arthritis is a systemic inflammatory disease which manifests itself in 
multiple joints of the body. The inflammatory process primarily affects the lining of the joints 
(synovial membrane), but can also affect other organs. The inflamed synovium leads to 
erosions of the cartilage and bone and sometimes joint deformity. Pain, swelling, and redness 
are common joint manifestations. Although the definitive causes are unknown, RA is 
believed to be the result of a faulty immune response. RA can begin at any age and is 
associated with fatigue and prolonged stiffness after rest. There is no cure for RA, but new 
drugs are increasingly available to treat the disease. In addition to medications and surgery, 
good self-management, including exercise, are known to reduce pain and disability. 
Definition: 
 A chronic autoimmune disease characterized by progressive arthritis of several small 
or medium-sized joints, especially in the hands. Symptoms can include morning stiffness, 
joint swelling and weakness, and deformity and disability. 
History: 
 The first known traces of Arthritis date back at least as far as 4500 BC. A text dated 
123 AD first describes symptoms very similar to Rheumatoid Arthritis. It was noted in 
skeletal remains of native americans found in tennessee. In the old world the disease is 
vanishingly rare before the 1600AD. And on this basis investigators believe it spread across 
the atlantic during the age of exploration. In 1859AD the disease acquired its current name. 
An anomaly has been noticed from investigation of precolumbian bones. The bones 
from the tennessee site show no signs of tuberculosis even though it was prevalent at the time 
throughout the America. Jim mobley has discovered a historical pattern of epidemics of 
tuberculosis followed by a surge in the number of Rheumatoid Arthritis cases a few 
generations later. Mobley attributes the spikes in arthritis to selective pressure caused by 
tuberculosis. A hypervigilant immune system is protective against tuberculosis at the cost of 
an increased risk of autoimmune disease. 
 The first recognized description of Rheumatoid Arthritis was in 1800 by the French 
physician Dr Augustin Jacob Landré-Beauvais (1772-1840) who was based in the famed 
Salpêtrière Hospital in Paris. The name "Rheumatoid Arthritis" itself was coined in 1859 by 
British Rheumatologist Dr Alfred Baring Garrod. 
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Epidemiology: 
The incidence of RA is in the region of 3 cases per 10,000 population per annum. 
Onset is uncommon under the age of 15 and from then on the incidence rises with age until 
the age of 80. The prevalence rate is 1%, with women affected three to five times as often as 
men. It is 4 times more common in smokers than non-smokers. 
 In India the prevalence of this disease affecting 0.75% of population. Projected to 
the whole population, this would give a total of about seven million patients. The prevalence 
of RA in India is quite similar to that reported from the developed countries. Some Native 
American groups have higher prevalence rates (5-6%) and people from the Caribbean region 
have lower prevalence rates. First-degree relatives prevalence rate is 2-3% and disease 
genetic concordance in monozygotic twins is approximately 15-20%. 
It is strongly associated with the inherited tissue type Major histocompatibility 
complex (MHC) antigen HLA-DR4 (most specifically DR0401 and 0404) — hence family 
history is an important risk factor. 
Clinical sign and symptoms: 
 Joint pain can be an early symptom of many different diseases. In rheumatoid 
arthritis, symptoms often develop slowly over a period of weeks or months. Fatigue and 
stiffness are usually early symptoms. Weight loss and a Low-grade fever can also occur. 
Joint symptoms include: 
Painful, swollen, tender, Stiff joints. The same joints on both sides of the body 
(symmetrical) are usually affected, especially the Hands, Wrists, Elbows, Feet, Ankles, 
Knees, or Neck. 
Morning stiffness, Joint stiffness may develop after long periods of sleeping or sitting. 
It lasts at least 60 minutes and often up to several hours. 
Rheumatoid nodules ranging in size from a pea to a mothball develop in nearly one-
third of people who have rheumatoid arthritis. Nodules usually form over pressure points in 
the body such as the elbows, knuckles, spine, and lower leg bones. In addition to specific 
joint symptoms, Rheumatoid Arthritis can cause symptoms throughout the body (systemic). 
These include: 
·  Fatigue, 
·  Loss of appetite, 
·  Weight loss, 
·  Mild fever. 
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 ` When the disease is active, symptoms can include fatigue, loss of energy, lack of 
appetite, low-grade fever, muscle and joint aches, and stiffness. Muscle and joint stiffness are 
usually most notable in the morning and after periods of inactivity. Arthritis is common 
during disease flares. Also during flares, joints frequently become red, swollen, painful and 
tender. This occurs because the lining tissue of the joint becomes inflamed, resulting in the 
production of excessive joint fluid. The synovium also thickens with inflammation. 
Comparing Rheumatoid Arthritis and Osteoarthritis - Topic Overview 
Rheumatoid Arthritis and osteoarthritis are different types of arthritis. Although they 
share some similar characteristics, each has different symptoms and requires different 
treatment. Therefore, an accurate diagnosis is important. 
Osteoarthritis is the most common form of arthritis. Rheumatoid arthritis affects about 
one-tenth as many people as osteoarthritis. The main difference between osteoarthritis and 
Rheumatoid Arthritis is the cause behind the joint symptoms. Osteoarthritis is caused by 
mechanical wear and tear on joints. Rheumatoid Arthritis is an autoimmune disease in which 
the body's own immune system attacks the body's joints. 
Etiology: 
The exact causes of RA are unknown. But research has shown that several factors 
may contribute to the development of RA: 
· Genetic - Certain genes play a role in the immune system - for some people, genetic factors 
may be involved in determining whether they will develop RA. 
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· Environmental - In people who have inherited a genetic tendency for the disease, RA can 
be triggered by an infection. However, RA is not contagious.  
Risk Factors of Rheumatoid Arthritis: 
Rheumatoid Arthritis is more common in women than in men. In fact, 70% of the 
patients with Rheumatoid Arthritis are women. In addition, there's an increased risk of 
Rheumatoid Arthritis in women who have never been pregnant and in those who have 
recently given birth. 
Rheumatoid Arthritis has a genetic link, and the disease can run in families. People 
with specific human leukocyte antigen (HLA) genes have a greater chance of developing 
Rheumatoid Arthritis than people who do not have the HLA genes. Still, not everyone with 
the HLA genes develops rheumatoid arthritis.  
Older age and cigarette smoking may increase the risk of getting Rheumatoid 
Arthritis. 
TRIGGERING FACTORS: 
· Infection  
· Vaccination 
· Physical trauma 
· Psychological stress 
PATHOPHYSIOLOGY 
Rheumatoid disease is considered to be an auto immune response to an unknown 
antigen and the antibody formed is the rheumatoid factor which is identified as 
immunoglobulin M or IgG. 
IMMUNOPATHOGENESIS: 
· In response to antigenic exposure (E.g.infectious agent) in a genetically predisposed 
individual (HLA-DR), CD4+ T-Cells are activated. 
· These cells elaborate cytokines, the important ones being tumour necrosis factor 
(TNF)-α, Interferon (IF)-γ, interleukin (IL)-1 and IL-6.These cytokines activate 
endothelial cells, B lymphocytes and macrophages. 
· Activation of B cells releases IgM antibody against IgG (i.e.anti-IgG) ; this molecule 
is termed rheumatoid factor (RF). 
· IgG and IgM immune complexes trigger inflammatory damage to the synovium, small 
blood vessels and collagen. 
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· Activated endothelial cells express adhesion molecules which stimulate collection of 
inflammatory cells. 
· Activation of macrophages releases more cytokines which cause damage to joint 
tissues and vascularisation of cartilage termed pannus formation.Eventually damage 
and destruction of bone and cartilage are followed by fibrosis and ankylosis producing 
joint deformities. 
STAGES IN PATHOLOLGY OF RHEUMATOID ARTHRITIS  
I. Pathology of Joints and Tendons. 
II. Pathology of Extra-articular tissues. 
I. PATHOLOGY OF JOINTS AND TENDONS  
It can be explained in three stages. 
1. Synovitis. 
2. Destruction. 
3. Deformity. 
1. Synovitis: 
Initial lesion occurs in the synovium, leading on to vascular stasis, and infiltration of the 
subsynovial layers with inflammatory cells and formation of fibrinous exudates. Synovial 
hypertrophy occurs with the thickening of capsular structures. 
Though this stage is painful, swollen and tender, their structures are still intact and 
mobile.  So, these disorders are reversibly potential. 
2. Destruction: 
Pannus formation: 
Hypertrophied synovium along with granulation tissue leads to formation of pannus 
which enroaches the articular cartilage from its periphery. 
Articular cartilage: 
The articular cartilage gets destroyed gradually.Further the bony surface is involved, 
leading to obliteration of joint face. Joint get destroyed and deformed. 
3. Deformity: 
The extending granular pannus gets into fibrous tissue, which bridges the articulating 
bone ends, leading to fibrous ankylosis and later bony ankyosis. 
Muscles, tendons, and soft tissues around the joint also undergo inflammatory 
changes and get contracted or ruptured. 
Juxta-articular osteoporosis occurs.Not all patients progress through all three stages. 
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THE HAND AND WRIST:  
As the disease progresses, joint activity limitation, thenar muscle atrophy, muscle 
imbalance between the forces, or damage to the articular surface can lead to many types of 
Rheumatoid hand deformities. 
1. Swan neck deformity                         5.  Boutonniere’s or button hole deformity 
2. Z deformity or hitch                           6.  Morant Baker’s cyst 
3. Equinus deformity                              7. Trigger finger 
4. Ulnar deviation of the hand  
Ankle, Toe joints:  
1. Callosity under pressure                                     8. Rheumatoid nodules  
2. Plantar callosity                                                   9. Calcaneal erosions 
3. Atrophy of plantar metatarsal fat pad.               10. Achilles tendinitis 
4. Prominent metatarsal head                                  11. Flattening of longitudinal arch 
5. Excessive plantar tilt of meta tarsals                 12. Bunion 
6. Claw toes                                                             13. Hallus valgus 
7. Hammer toes                                                       14. Over- riding of 2 and 3 toes. 
Sjogren's syndrome:  
Since Rheumatoid Arthritis is a systemic disease, its inflammation can affect organs and 
areas of the body other than the joints. Inflammation of the glands of the eyes and mouth can 
cause dryness of these areas and is referred to as Sjogren's syndrome. Dryness of the eyes can 
lead to corneal abrasion. Inflammation of the white parts of the eyes is referred to 
asscleritis and can be very dangerous to the eye.  
Pericarditis: 
Rheumatoid inflammation of the lung lining causes chest pain with deep 
breathing, shortness of breath, or coughing. The lung tissue itself can also become inflamed, 
scarred, and sometimes nodules of inflammation develop within the lungs. Inflammation of 
the tissue surrounding the heart, called pericarditis, can cause a chest pain that typically 
changes in intensity when lying down or leaning forward.  
Rheumatoid Arthritis is associated with an increase risk for heart attack. 
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Felty's syndrome:  
Rheumatoid disease can reduce the number of red blood cells and white blood cells. 
Decreased white cells can be associated with an enlarged spleen referred to as Felty's 
syndrome and can increase the risk of infections.  
Cancer: 
The risk of lymph gland cancer is higher in patients with rheumatoid arthritis, 
especially in those with sustained active joint inflammation. Firm lumps under the skin can 
occur around the elbows and fingers where there is frequent pressure.  
Carpal Tunnel Syndrome: 
Even though these nodules usually do not cause symptoms, occasionally they can 
become infected. Nerves can become pinched in the wrists to cause carpal tunnel syndrome. 
Vasculitis:  
A rare, serious complication, usually with longstanding rheumatoid disease, is blood 
vessel inflammation called Vasculitis and it  can impair blood supply to tissues and lead to 
tissue death. This is most often initially visible as tiny black areas around the nail beds or 
as leg ulcers. 
Diagnostic criteria:  
 The diagnosis of RA can be made when the following clinical features are all present: 
§ Inflammatory arthritis involving three or more joints.  
§ Positive rheumatoid factor (RF) and/or anti-citrullinated peptide/protein antibody 
(such as anti-CCP).  
§ Elevated levels of C-reactive protein (CRP) or the erythrocyte sedimentation rate 
(ESR).  
§ Diseases with similar clinical features have been excluded, particularly psoriatic 
arthritis, acute viral polyarthritis, polyarticular gout or calcium pyrophosphate 
deposition disease, and systemic lupus erythematosus. 
§ The duration of symptoms is more than six weeks. 
The diagnosis of RA may also be made in some patients who do not meet all the criteria.  
DIFFERENTIAL DIAGNOSIS  
 Several other medical conditions can resemble RA, and usually need to be distinguished 
from it at the time of diagnosis.  
· Crystal induced arthritis (Gout, and Pseudogout): It usually involves particular 
joints (knee, Meta tarsal phalanges, heels) and can be distinguished with aspiration of 
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joint fluid if in doubt. Redness (RA doesn't have redness at the joints), asymmetric 
distribution of affected joints, pain occurs at night and the starting pain is less than an 
hour with gout. 
· Osteoarthritis : Distinguished with X-rays of the affected joints and blood tests, age 
(mostly older patients), starting pain less than an hour, asymmetric distribution of 
affected joints and pain worsens when using joint for longer periods. 
· Systemic Lupus Erythematosus (SLE): Distinguished by specific clinical symptoms 
and blood tests (antibodies against double-stranded DNA). 
· Psoriatic arthritis: Resembles RA nail changes and skin symptoms distinguish 
between them. 
· Reactive Arthritis (previously Reiter's disease): Asymmetrically involves 
heel, sacroiliac joints, and large joints of the leg. It is usually associated 
with urethritis, conjunctivitis, iritis, painless buccal ulcers, and keratoderma 
blennorrhagica. 
· Ankylosing spondylitis: This involves the spine, although a RA-like symmetrical 
small-joint polyarthritis may occur in the context of this condition. 
· Hepatitis C : Hepatitis C may also induce Rheumatoid Factor auto-antibodies. 
· Sarcoidosis, Amyloidosis and Whipple's disease can also resemble RA. 
· Hemochromatosis may cause hand joint arthritis. 
· Acute Rheumatic fever can be differentiated from RA by a migratory pattern of joint 
involvement and evidence of antecedent streptococcal infection. Bacterial arthritis is 
usually asymmetric, while RA usually involves both sides of the body symmetrically. 
LABORATORY INVESTIGATIONS: 
I.BLOOD 
1. Complete Blood Count   
Haemoglobin      - Anaemia  
  Thrombocytes     - Thrombocytosis  
  ESR                 - Increased  
2. Serum proteins: 
Albumin   - Decreased 
Gamma globulin       - Increased 
IgG, IgM, IgA  - Increased 
3.Serological tests: 
21 
 
Rheumatoid Factor: 
 Rheumatoid factor measures how many of one type of antibodies (IgM, sometimes 
IgA) binds to a second type of your antibodies (IgG). Initially, only one third of people with 
RA test positive for the set of antibody called the Rheumatoid Factor (RF). 
Most people with Rheumatoid Arthritis will eventually develop this marker and a 
positive RF is considered a sign and symptom of rheumatoid arthritis. However, some people 
test positive for rheumatoid factor, yet never develop the disease.  
Anti-CCP: 
 These anti-CCP antibodies bind to some self proteins that are found predominately in 
the synovial tissue. The citrullinated proteins include filaggrin and its circular form (cyclic 
citrullinated peptide: CCP). The presence of these antibodies often correlates with some joint 
destruction. Although this test is relatively recent, a high level of anti-CCP is considered a 
sign and symptom of Rheumatoid Arthritis. 
Inflammation:  
 Inflammation is your body’s response to damage. Your body sends in certain types of 
white blood cells to pick up debris, fight off infection, promote healing and, if needed, bring 
in more blood vessels. There is usually a higher state of inflammation in Rheumatoid 
Arthritis patients and it is a classic sign and symptom of Rheumatoid Arthritis.  
Erythrocyte sedimentation rate:  
It measures the quantity and how quickly the cells are pelleted by spinning in a 
centrifuge. Indirectly, it measures how many cells are bigger and thus activated. 
C-reactive protein.  
A higher than normal level of C-reactive protein (CRP) in the blood also indicates that 
your body has chronic inflammation, and is a common sign and symptom of Rheumatoid 
Arthritis.  
Radiology: 
X-rays 
X-rays of all your joints can determine the extent of damage in the joints that are 
affected. A sequence of X-rays obtained over time can show the progression of RA. 
Other investigations: 
Urine: 
Proteinuria may be due to nephrotic syndrome associated with connective tissue 
disease. 
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Synovial fluid: 
· White cell count raised in infection. 
· Gram stains, culture and sensitivities. 
· Crystal identification: Presence of Urate, Calcium pyrophosphate,crystals present. 
· Synovial fluid analysis confirms the presence of inflammatory arthritis. Fluid may 
show positive rose-waaler test in joint fluid, before it can be detected in blood. Also it 
may show neutrophils or monocytes inclusion bodies. 
Biopsy: 
§ Synovial biopsy: Villi formation with thickening of synovial layer and infiltration 
with abnormal cells. 
§ Renal Biopsy: Indicated in cases of reduced tubular or glomerular function. 
Pulmonary Biopsy: Used to distinguish rheumatoid nodules from carcinoma or to 
establish diagnosis of fibrosing alveolitis. 
 
 
 
 
 
 
 
 
PHOTOS OF THE DEFORMITIES 
                      
BOUTONNIERE’S DEFORMITY                         EXCESSIVE PLANTAR TILT OF  
META TARSALS                    
 
              
SPINDLE SHAPE DEMORMITY   SWAN NECK DEFORMITY                          
 
 
             
Z SHAPED DEFORMITY     AFFECTED ELBOW JOINT 
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PREPARATION AND PROPERTIES OF TRIAL DRUG 
PREPARATION OF TRIAL DRUG 
«Á¢÷¾Ãºõ 
 
“¸ó¾¸õ µ÷ÀíÌ ¸¢Ç÷Ý¾õ ®÷ÀíÌ 
¾ó¾×Ã¢î º¡üÈ¢Ä¨¾ò ¾¡É¨ÃòÐ - Åó§¾¡ðÊø 
¨Åò¾ÉÄ¢ §ÄÅÚòÐ ÅýÀ¾ò¾¢ §É¡¦¼ÎòÐ 
¦Áò¾×ó àÉ¢îº¡Ú Å¢ðÎ.” 
 
“Å¢ð¼¨ÃòÐì ÌýÈ¢¦Â¨¼ Å¢ûÁ¡ò¾¢¨ÃÀ¢Êò§¾ 
þð¼Ó¼ý ´ÕÕñ¨¼ þðÊ¼§Å - ¦¾¡ð¼ÍÃõ 
ºýÉ¢ ±Ø§¾¡¼õ ¾ýÅ¡¾õ§À¡ Á¢¾ý§À÷ 
±ñ½¢ ÄÁ¢÷¾Ãºõ ²óÐ.” 
    -«¸Š¾¢Â÷ Á½¢4000 ±ýÛõ ¨Åò¾¢Â º¢ó¾¡Á½¢      
            ¦ÅñÀ¡4000 þÃñ¼¡õ À¡¸õ Àì¸õ 37-38. 
 
A. INTERNAL MEDICINE: AMIRTHARASA  MATHIRAI  
Ingredients: 
·   Purified Rasam( Mercury )                                -  70 gms 
·   Purified Gandagam (Sulphur)                           -  35 gms 
·   Avuri leaf juice (Indigofera tinctoria,Linn.)     - Quantity sufficient.           
PURIFICATION OF RAW DRUGS: 
1. Purification of Rasam (mercury): 
35 gms of Mercury is taken, ground with brick powder and turmeric powder 
consecutively for about 1 hour. Then it is washed with water then mixed with 1.3 liters of 
Kuppai meni juice (Acalypha indica) and is heated until the juice dries completely. 
                                                            - Reference: Gunapadam Thadhu Jeeva Vaguppu(Pg No:245) 
2. Purification of Ganthagam (Sulphur): 
Sulphur is taken in an iron ladle along with cow’s butter and subjected to heat upto 
melting then it is poured into cow’s milk. This process is repeated for 9 more times. Then the 
sulphur is taken out and dried to get it in purified form. 
                                                          - Reference : Gunapadam Thadhu Jeeva Vaguppu(Pg No:305)  
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METHOD OF PREPARATION: 
Purified Mercury and purified Sulphur are ground  to fine powder well using Avuri 
charu, and then taken in a mud plate subjected to heat,which is again  ground well using 
Avuri charu and made into pills (size –kundrimani 130mgs) 
                                    (Reference: Agathiyar Mani 4000 ennum Vaithiya Chinthamani  
         Venbaa 4000 part -2 Pg no 37-38)     
Í§Ã¡½¢¾ Å¡¾ ±ñ¦½ö 
“±Õì¸¢¨Ä §Å¨Ç ¦¿¡îº¢ ÔÇ¢Â¢¨Ä º×Ã¢ì ¦¸¡òÐ 
¿Õì¸¢Â ¿¡Ä¢¦Ä¡ýÚ ¦¸¡Ç ¦ÅûÇ¡ðÎô À¡ 
ÖÕìÌÁ¡ Á½ì¸¢ ¦Éñ¦½ö ´ýÚ¼ý ¸ÄóÐ ¸¡öîº¢ 
ºÕì¦¸Éò §¾¸ò¾¢ü âºò àÃô§À¡ï Í§Ã¡½¢¾ Å¡¾õ.’ 
          -§¾¨ÃÂ÷ Å¡¸¼õ ãÄÓõ ¯¨ÃÔõ Àì¸õ 64-65 
B. External Medicine: SURONITHA VATHA ENNAI. 
Ingredients: 
1. Erukku  leaf (Calotropis gigantean (linn) R.B  -        500gm 
2. Vaelai leaf (Cleome viscose,Linn.)                         -        500gm 
3. Notchi leaf (Vitex negundo,Linn.)                                   -        500gm 
4. Pulli leaf (Tamarindus indica.Linn.)                                -        500gm 
5. Savri leaf (Trichosanthes tricuspidata)              -        500gm 
6. Goats milk                                                                         -       0.625ml 
7. Castor oil (Ricinus communis,Linn.)                                 -       0.625ml 
Method of Preparation:                                        
All the above said ingredients except goats milk and castor oil is first made into 
decotion form then mixed with Goats milk and castor oil, subjected to heat and then filtered 
in thylam form.  
           - Reference: Theraiyar  Vaagadam (Pg 64-65) 
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PROPERTIES OF THE INGREDIENTS OF  TRIAL DRUGS 
1. RASAM 
English name  :  Mercury, Quick Silver 
Chemical name :  Hydrar gyrum 
Organoleptic Characters 
Taste  :  Six tastes – dominated by sweet 
Potency :  Hot and Cold 
Actions :  Tonic, Vitalizer, Diuretic, Silogogue, Anti inflammatory, 
Neutralizing  pitha.  
Types   : Rasam, Rasendhiran, Sootham, Misragam, Baaratham. 
 The Mercury is the chief of all elements. It gives good health, protects the body and 
cures the diseases that affect the body. Further it facilitates to attain the eight folded siddhis. 
General properties: 
“Å¢Æ¢§¿¡ö ¸¢Ãó¾¢ÌýÁõ ¦ÁöîÝ¨Ä ÒñÌð 
¼Æ¢¸¡Ä¢ø Å¢óÐÅ¢É¡ø «ò¨¾ - ÅÆ¢Â¡ö  
ÒÃ¢Ô Å¢¾¢ Â¡Ð ÒÃ¢Â¢§É¡ ¦ÂøÄ¡õ 
þÃ¢Ô Å¢¾¢ Â¡Ð Á¢ø¨Ä.” 
                        -Ì½À¡¼õ ¾¡Ð ÅÌôÒ.    
 Proper use of Mercury as medicine cures the diseases of eyes, syphilis, eight types of 
ulcers (Gunmam) and Throbbing pain (Soolai). 
Beneficial properties: 
· It purifies blood, it improves blood and sperms.  
· Stimulates appetite.  
· Kills the micro-organisms and cures the ulcers. 
· It cures the diseases of internal and external organs of the body. 
· It improves facial complexion. 
· It improves memory power, eradicates amnesia.  
· It strengthens the nerve plexuses. 
· It develops wisdom through concentration of mind. 
· It prevents senility and increases the life span. 
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Special properties: 
 Mercury has speciality to cure all diseases which is caused by the variation in the 
Mukkutram. 
2. GANDHAGAM 
English name  :  Sulphur 
Organoleptic Characters 
Taste  :   Bitter and Astringent 
Potency :   Hot and Cold 
Pirivu   : Kaarppu ( Pungent) 
Actions  :   Laxative,  
Tonic,  
Antiseptic,  
Diaphoretic, 
 Cholagogue. 
Types   :  Pirappu, Vaippu, Nellikkai, Vaana. 
Nellikkai Gandhagam is the one which is often used in medicine preparations. 
General properties: 
“¦¿øÄ¢ì¸¡öì ¸ó¾¢ìÌ ¿£ûÀ¾¢¦½ý Ìð¼ Áó¾õ 
Åø¨Ä ¸Å¢¨ºÌýÁ Å¡Ô¸ñ§½¡ö - ¦À¡øÄ¡ 
Å¢¼ì¸Ê Åý §Á¸§¿¡ö Å£ÚÍÃõ §À¾¢ 
¾¢¼ì¸¢Ã¸ ½£¸Àõ§À¡ó §¾÷.” 
      -Ì½À¡¼õ ¾¡Ð ÅÌôÒ. 
It is useful in the treatment of 18 types of Skin Diseases, Liver Enlargement, 
Abdominal Distention, Eye Diseases, Chronic Venereal Diseases, Chronic Diarrhoea, Gastric 
Ulcer, Poisonous Bites, Fever due to Vatham and Chronic Dysentery. 
Special properties 
Sulphur as an internal medicine heals the diseases effectively in a way similar to that 
of mother’s care. 
3. AVURI 
English name  :  Indian Indigo plant 
Botanical name :  Indigofera tinctoria 
Family  : Fabaceae 
Parts used  :  Whole plant 
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Organoleptic Characters 
Taste  :   Kaippu 
Potency :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions 
  Germicide,   
      Antiperiodic,    
    Stimulant.   
Therapeutic effects 
  “¯Ã¢ÂÄ× Ã¢ò¾¨Æò¾¡ý µÐ À¾¢¦Éñ 
  «Ã¢Â¿ï¨ºò ¾¢ýÈÅ÷ìÌõ ¬Ìõ - ¦¾Ã¢ÅÃ¢Â 
  Å¡¾¦ÅôÒ ¸¡Á¡¨Ä ¨Áó¾÷ ÌÚÁ¡ó¾ï 
  º£¾õ «¸üÚó ¦¾Ã¢.” 
 
  “ºýÉ¢ À¾¢ãýÚï ºó¦¾¡Êò¾ Å¡¾Ó¾ø 
  ¯ýÛ Å¢¼ì¸ÊÔõ µÎí¸¡ñ - Á¢ýÛí 
  ¸×Ã¢¿¢Èõ ¯ñ¼¡Ìõ ¸¡º¢É¢Ôû ¿øÄ 
  «×Ã¢Â¢¨Ä ¾ýÉ¡ø «È¢.” 
        -«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Avuri leaf decoction cures, 18 types of toxins, fever, jaundice and Vatham.  
4.ERUKKU 
English name  :  Mudar, Gigantic swallow wort 
Botanical name :  Calotropis gigantes ( Linn) R.Br. 
Family  : Asclepiadaceae 
Parts used  :  Leaf  
Organoleptic Characters 
Taste  :   Kaippu, Kaarppu, Inippu 
Potency :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions 
    Anthelmintic,   
    Alterative,      
   Laxative.  
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Therapeutic effects 
“±Ä¢Å¢¼í Ìð¼¨ÁÂ §ÁÚ ¸¢ÕÁ¢ 
ÅÄ¢Ý¨Ä Å¡ÔÅ¢¼ Áó¾õ - ÁÄÀó¾õ 
±øÄ¡ Á¸Ö ¦ÁÕì¸¢¨Ä ¨Âì¸ñ¼¡ø 
Å¢øÄ¡÷ Ñ¾§Ä! Å¢ÇõÒ.” 
-«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Its leaves cures Rat poison, snake poison, Joint pain and Vatham. 
 
5. VELAI 
English name  :  Dog mustard 
Botanical name :  Cleome viscosa.Linn. 
Family  : Cleomaceae 
Parts used  :  Leaf  
Organoleptic Characters 
Taste  :   Kaarppu 
Potency :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions 
   Rubefacient,   
    Antispasmodic,     
    Carminative, 
    Diaphoretic.   
Therapeutic effects 
“º¢Ã§¿¡ö ÅÄ¢Ì¨¼îºø ¾£Ã¡î ºÂ¢ò¾¢Âõ 
¯Ã§¿¡ Â¢¨Å¸ ¦Ç¡Æ¢Ôõ - ¯Ã§Á×õ 
Å¢ø§Å¨Çì ¸¡Ôõ Å¢Æ¢Â¡ö! Àº¢¦¸¡ÎìÌõ 
¿ø§Å¨Ç ¾ý¨É ¿Å¢ø.” 
 
“¿øÄ§Å ¨Çôâñ¨¼ ¿¡Îí¸¡ø Å¡¾Óõ§À¡õ 
¦º¡øÖ¨Á ÂòÐ¼§É §º¡¨ÀÂÚõ - ¦ÁøÄ¦ÁøÄ 
¾ì¸ ÅÉ ÖõÀ¢òÐó ¾¡¦ÉØõÒïº¡ó¾Á¢ýÈ¢ 
«ì¸Ã§¿¡ö Á¢ïÍ ÁÈ¢.” 
-«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 It cures Head ache, Body pain, stabbing pain, chest pain and reducing Vatham. 
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6. NOTCHI 
English name  :  Five leaved chaste tree 
Botanical name :  Vitex negundo.Linn. 
Family  : Verbenaceae 
Parts used  :  Leaf 
Organoleptic Characters 
Taste  :  Kaippu,Thuvarppu, Kaarppu. 
Potency :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions 
     Alterative, 
     Vermifuge, 
     Astringent, 
     Refrigerant.  
Therapeutic effects 
“§¿¡Â¡ ¸Ä¢¨Â ¦¿¡ÊìÌ ÇÕó¾¦Åõ¨Á 
§Â¡Â¡ Á½¡Ù ÓÂ÷òÐ¾Öì - ¸¡Â 
Åó¾Ó¾ø ¿ñÀ¡¸¢ Å¡¾ò¨¾ §ÂÔÈÅ¡ü 
º¢óÐÅ¡ Ãí¸ÉÖó ¾£.” 
                       -§¾Ãý ¦ÅñÀ¡ 
It  reduces the Vatha kutram, Body pain, Joints pain and Swelling due to vatham. 
7. PULI ELAI 
English name  :  Tamarind tree 
Botanical name :  Tamarindus indica.Linn. 
Family  : Caesalpiniaceae 
Parts used  :  Leaf 
Organoleptic Characters 
Taste  :   Pullipu 
Potency :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions 
     Laxative, 
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     Stimulant, 
     Refrigerant.  
Therapeutic effects 
“¾£¾¢ø ÀÆõÒÇ¢¨Âî §º÷ì¸ò ¾¢Ã¢§¾¡¼õ 
Å¡¾¦Á¡Î Ý¨Ä¸Àõ Á¡Úí¸¡ñ - µÐÍÃï 
º÷ò¾¢¦ÂýÈ §¾¡¼Á¢¨Å º¡ó¾Á¡í ¸ñ§½¡ö§À¡õ 
À¢ò¾¦ÁýÈ §À¦Ã¡Æ¢Ôõ §ÀÍ.” 
              -«¸ò¾¢Â÷ Ì½Å¡¸¼õ. 
It cures Vatha diseases, Mukkutram, Vomiting, Eye diseases and  Fever. 
By using leaf as a external application it reduces swelling due to vatham and also reduces 
pain.  
8.SAVURI 
English name  :  Kurattai 
Botanical name :  Trichosanthes bracteata (Lam) 
Family  : Cucurbitaceae 
Parts used  :   Leaf  
Organoleptic Characters 
Taste  :   Kaippu 
Potency :   Veppam 
Pirivu  :   Kaarppu 
Therapeutic actions 
     Hydragogue, 
      Cathartic, 
      Counter irritant. 
Therapeutic effects 
“¾¨ÄÅÄ¢Ì ¨¼îºø ºÄôÀ£É ºí¸û 
Ì¨ÄÌ¨ÄóÐ ¸¡ðÊü ÌÊ§À¡õ -¿¢¨ÄÅ¡ 
ÉÅÃ¢ô ÀÊÁ¡¦¾ý ¨ÈÔÚ¦Áöõ Á¡§¾! 
ºÅÃ¢ô ÀÆò¾¡û º¨ÇóÐ.” 
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9.GOATS MILK 
Therapeutic effects 
"¦ÅûÇ¡ðÎ À¡ÖìÌ §ÁÅ¢Â¿ü È£ÀÉÁ¡ó 
¾ûÇ¡Î Å¡¾À¢ò¾ï º¡ó¾Á¡õ - ¯ûÇ¢¨ÃôÒî 
§º¾Á¾¢ º¡Ãï º¢§ÄÐÁõ «Úõ Òñ½¡êõ 
Å¡¾ º¢§ÄÐÁõ Óô§À¡ Á¡öóÐ". 
                -Ì½À¡¼õ º£Å ÅÌôÒ  
Goats milk cures vathapitha diseases, bronchial asthma, dysentery, kabam diseases, ulcers, 
 and it reducing Swelling due to vatham. 
 
10.CASTOR OIL 
 
English name  :  Caster oil 
Botanical name :  Ricinus communis  Linn. 
Family  :  Euphorbiaceae 
Parts used  :  Leaf  
Organoleptic Characters 
Taste  :   Kaippu 
Potency :  Veppam 
Pirivu  :  Kaarppu 
Therapeutic Action: 
  `  Anti vatha, 
    Galactagogue. 
Therapeutic effects 
  “¬Á½ì ¦¸ñ¦½ö ¾ý¨É Â  Ä Á Âì §¸ñ ý 
âÁ½î ºóÐ §த¡Úõ ¦À¡Õó Â Å¡¾õ §À¡ìÌõ 
 Áó¾ò ¾¡Ûõ §À¡ìÌó  ¸ú×¼ý  ¨Ã× Óñ¼¡õ 
 ÁÉì Ì¼ ø Å¡¾ï §º÷Ì¼ §ÄüÈõ §À¡§Á. '' 
               -Ì½À¡¼ ã ¨¸ ÅÌôÒ  
This oil reduces the all major and minor joint pain, vatham and abdominal 
discomfort due to the variations in vatham. 
By having purgative action it reduces the constipation, vatham and flatulence. 
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Chemical constituents  
Ø Ricinus communis Seeds contain fixed oil 45 -52 %.  
Ø The oil chiefly consists of ricinoleate glycerol or tri – ricinoleate of glycerol or tri-
ricinolein, with a small quantity of palmitin, stearin. 
Ø The glycerides of ricinoleic acid are mainly responsible for the purgative effect. 
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VARMAM 
Varmam is a art of defence. The changes occurring in the body on being hit at some 
specific points on the body indirectly with a particular force is known as varmam. 
The changes occurring in the body vary with the force  of  hitting, time or duration 
and the physical strength of the victim. 
The points where life force resides and flows in the human body are known as 
varmam. Varmam also means the points where breathing energy resides in the body. 
          -Vaagada Nithaanam Verse- 31 
                              “Å¡º¢ ¾ðÎõ ¾Ä¦ÁøÄ¡õ Å÷Áõ.”                         
    - Varma Odivu Murivu Sara Soothiram-1200 
  Varmam can be defined as the flow of  life force in relationship with breathing. 
                           “¦ºôÒÚ ¾¨º¸¦ÇýÒ º¢Ú ¦ÀÕ ¿ÃõÒºóÐ 
                        ¾ôÒÚ ¿¡ÊÂ¡Úõ ¾íÌÁ¢¼õ ÅýÁÁ¡§Á.”  
                                                -Varma Vidhi 
            The vital points (varmams) are located in the junction of nerves, joints, bones, 
muscles, ligaments and internal organs. 
Synonyms of the varmam 
 The equivalent terms denoting varmam are Kaalam, Adakkam, Marmam, Sutcham, 
Vanmam, Emam, Idu,Vaasi,Puravi,Uyir etc, 
HISTORY OF VARMAM:            
                              "§¾È§Å º¢Åý ¯¨ÁìÌî ¦º¡ýÉ §À¡¾õ  
                 ¬È¡Áø ¿¡ý «È¢óÐ þóáø ¦º¡ý§Éý." 
       - Varma Odivu Murivu Sara Soothiram-1500, Song-833 
           Lord Siva taught varmam to his wife Paarvathi; later Paarvathi taught varmam to their 
son Lord Murugan. Lord Murugan then taught to the Siddhar Agasthiyar. Agasthiyar later 
gave a written form that reached the people. 
CLASSIFICATION OF VARMAM DEAL BY VARIOUS TEXTS: 
          There are 108 varmam or varma points in our body.  
    1. According to the text Varma Odivu Murivu Soothiram, 
1. Padu varmam        - 12 
2. Thodu varmam      - 96 
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            Paduvarmam (12) which are injured, can lead to death. The other 96 are 
Thoduvarmam which are used in therapeutic purposes. 
    3. According to the text Varma Soothiram, 
 Vatha varmam      -  64 
 Pittha varmam     -  24 
 Kaba varmam        -  06 
 Ul varmam            -  06 
 Thattu varmam     -  08 
                         Total             - 108 
The main causes for impact to nerve centre (Varmam) 
“§¸ÇôÀ¡ ¾ÊÂÊ¸û ÀÎ¾ Ä¡Öõ 
    ¦¸ÊÂ¡É ±È¢Å¢¨º¸û ¦¸¡ûÇ Ä¡Öõ 
 Å¡ÇôÀ¡ ¸ð¨¼ÌüÈ¢ ¾ð¼ Ä¡Öõ  
    Á¡üÈ¡É¢ý ¨¸ôÀ¢Ê¸û ÀÎ¾Ä¡Öõ  
 §ÅÇôÀ¡ ¬¸º¡ Á¾¢§Ä ¿¢ýÚ 
    ¦ÁöÁÈóÐ ¨¸ÁÈóÐ Å¢Ø¾ Ä¡Öõ 
 ¾¡ÇôÀ¡ ÀüÀÄÅ¡õ Å¢¾ò¾¢ É¡§Ä 
    ºí¨¸Â¢øÄ¡ì ¸¡ÄÁÐ º¡Õó ¾¡§É.”  
                                -Odivu Murivu Saari-1200 
· Hit sustained by a thick and rough stick.  
· Stone thrown at a high speed from a sling.  
· Fall from a tree or height. 
· Fall while running. 
· By leaping.  
· By fainting.           
Varmam treatment 
                  Varmam therapy is a systematic study of vital points (varmam) on human body 
and also on animal bodies. 
       “¯ûÇÀÊ áü¦ÈðÎ ¾Äõ º¡Å¡Ìõ 
    ¯½÷Å¡¸¢ «ò¾Äí¸û ¯Â¢Õ Á¡Ìõ  
  ¸ûÇÓüÈ «ò¾Äí¸û À¢½¢Ô Á¡Ìõ  
    ¸Çí¸ÁüÈ¡ø «ò¾Äí¸û Í¸§Á ¸¡Ïõ  
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     ¯ûÙ½÷Å¡ö «ò¾Äí¸û Å¡º¢ §ÂüÈ 
                   ¯üÈ¾¢É¡ø «ò¾Äí¸û ¯Ú¾¢ §ºÕõ  
              ÒûÇÊ§À¡ø «ò¾Äí¸û ¸ñ¼ Å÷¸û 
                   Ò¸Ä¡÷¸û ±ø§Ä¡Õõ ÒÅ¢Â¢Ûû §Ç¡÷ì§¸."  
                               -Varma Odivu Murivu Sara Soothiram-1200   
            It is also called the art of killing and the art of healing. Right or wrong vibration of the 
vital points will either promote or impair health and aim is to produce healthy and stable 
individuals.   
Varmam treatment is connected with medicines, yoga, therapeutic massage, astrology, 
psychology, sociology, martial Arts etc.  
The 40 cases of the Uthiravatha Suronitham were diagnosed clinically and 20 cases of 
them were admitted in Ayothidoss Pandithar Hospital attached to National Institute of 
Siddha. Among them 10 Inpatients were treated  by Varmam treatment along with the trial 
drugs. The remaining 10 Inpatients received only trial medicines. 
Varmam points manipulated in Uthiravatha Suronitham patients once a day. 
1.Mudichi   
2.Kavuli 
3.Chavvu 
4.Mozhi piralgai 
5.Komberi 
6.Viruthi 
7.Ullangal velli 
8.Ullangai vellai 
                                                             1. MUDICHU VARMAM 
Synonyms: 
· Pinmudichu varmam  
· Kabalamudichu varmam (Thodu varma nithanam) 
· Pinsuvathi varmam (Varma nithanam) 
Location: 
"À¢¼È¢Â¢ý §Áø ¿¡Ä¢¨ÈÂ¢ø ÓÊîÍ Å÷Áõ". 
-  Å÷Á º¡Ã¢ 205 
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"§¸Ç¼¡ À¢Èó¾¨ÄÂ¢ø ¦À¡Õò¾¢ø ¾¡§É 
   ¸¢Õ¨ÀÔ¼ý À¢ý ÍÅ¡¾¢ ±ýÈ¾üÌô §ÀÃ¡õ". 
- Å÷Á ¿¢¾¡Éõ. 
Muduchi:  
It is located in nape at the bony prominence of cervical region. 
2. KAVULI  KAALAM 
Synonyms: 
· Chipiram ( Varma vidhi ) 
· Kavuli kaalam ( Varma suthiram 101 ) 
Location: 
"Å¢ð¼ ¨¸Â¢É¢¨¼ ¸ÅÇ¢ ãÛõ ¸¡§½". 
- Å÷Á ¾¢È×§¸¡ø 225 
"¸üÀ¦ÁýÉ ¨¸Â¢¨¼Â¢ø ¸ÅÇ¢¸¡Äõ". 
- Å÷Á Ýò¾¢Ãõ 101 
"¦¸¡ñ¼¦¾¡÷ ¦ÀÕÅ¢ÃÖìÌ ¸£Æ¢§Ä ¸ÅÇ¢¦ÂýÚõ 
 ¸ñÊ¼¡ ¿ÎÅ¢ÃÖìÌõ ¸£§Æ þÕÅ¨¸ ¾¡ý". 
- Å÷Á Ä¡¼ Ýò¾¢Ãõ 300. 
Kavuli varam: 
It is located above the web space of fingers. For ceganavatham pressure is applied in 
kavuli between thumb and index finger. 
3. CHAVU VARMAM 
Synonyms: 
· Paadhaipu varmam ( Varma noolalavu nool ) 
· Sanni varmam ( Varma nithanam 300 ) 
Location: 
"ÓðÎ º¢Ãð¨¼ ÍüÈÇ¦ÅÎòÐ (ÍÁ¡÷ 18 Å¢ÃÄÇ×) ãýÈ¡¸ Á¼ì¸¢  
(ÍÁ¡÷ 6 Å¢ÃÄÇ×) ÓðÎ º¢Ãð¨¼Â¢Ä¢ÕóÐ þÕ Àì¸Å¡ðÊÖõ «Çì¸  
ÅÄÐ ÒÈÓõ þ¼Ð ÒÈÓõ À¨¾ôÒ Å÷Áõ «È¢ÂÄ¡õ" 
                    - Å÷Á áÄÇ× áø. 
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Chavu: 
It is located in medial aspect of arm just below the shoulder. 
 
4. MOZHI PIRALGAI: 
Synonyms: 
· Mozhi varmam (varma beerangi 100) 
· Mozhi pooruthu varmam (varma noolalavu nool) 
· Singara manikattu kaalam (sathuramani suthiram) 
Location: 
"Å¡ÃÓÚ ¸ÃÁ¾¢§Ä ÆíÌÄò¾¢ø 
¦Á¡Æ¢ À¢Èí¸ñ ¦¾ðº¨½Â¢ý ¸¡Ä¦ÁýÀ÷" 
          - Å÷Á À£Ãí¸¢ 100 
"Å¡Ã¡É ¸ÃÁ¾¢§Ä ²Øõ ¾¡Ûõ 
  Å¡úòÐ¸¢§È¡õ ¦Á¡Æ¢ À¢È¸ñ¦¾ðº¨½" 
- Å÷õ ¸ñ½¡Ê 500 
"¦º¡÷½ ¦¾îº¨½ì ¸¡ÄòÐìÌ ¿Î§Å 
  º¢í¸¡¼ Á½¢¸ðÎ ¸¡Äõ þÐ ¦¾¡ÎÅ÷Áõ" 
- Å÷Á Å¢ÃÄÇ× áø 
Mozhi Piralgai 
 It is located in the web space at the junction of thumb and Index finger.  
       
   5.KOMBERI VARMAM 
Synonyms:  
Thumbikaala varmam  - Varma Noolavu Nool 
Komberi varmam          - Varma Soothiram  
Location: 
                          “Ì¾¢¨ÃÓ¸ Å÷Áò¾¢Ä¢ÕóÐ (5 Å¢ÃÖìÌ) ¸£ú§¿¡ì¸¢ 
            «Çì¸ ÐõÀ¢ì¸¡Ä Å÷Áõ «È¢ÂÄ¡õ.” 
                                       -Varma Noolalavu Nool  
               “................................Ì¾¢¨Ã Ó¸Å÷Áõ 
 ¸ñ¼¡§Â «íÌÄó¾¡ý ¿¡Ä¢ý ¸£§Æ 
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 ¸¼ó¾¢ð¼¡ø ¦¸¡õ§ÀÈ¢ Å÷ÁÁ¡Ìõ 
              ²Ìõ Ó¼× þ¨ÈÃñÊø ÐõÀ¢¸¡Äõ.” 
                                                -Adi Varma Sootcham-500 
           “¸¡Ä¢§Ä Ì¾¢¨ÃÓ¸ì ¸¡Äò¾¢ý ¸£ú «íÌÄõ   
                    ¿¡Ä¢§Ä ¿Å¢Ö§Å¡õ ¦¸¡õ¦ÀÈ¢ Å÷Áò¾¢ý ¾¡Éõ.” 
                            -Varma Laada Soothiram-300 
                  Komberi varmam  is located  5 fingers below from the Kuthirai Mugha Varmam 
point (the middle of the both legs) in the anterior aspect of both legs. 
Sign and symptoms: 
Damage to Komberi Varmam leads to sweating, features  mimicking tetanus and 
tiredness will set in. 
Uses: 
                It reduces the back pain.                                
                                             -Practical guidance given by  Thiru.Shanmugam Aasaan 
6. VIRUTTHI VARMAM 
Synonyms:  
 Virdhi varmam   - Varma Kannaadi 500 
           Virtthi varmam   - Adi Varma Soothiram 
        Viruthi varmam  - Varma Laada Soothiram 300  
Location:  
                   “¿Å¢Ö¸¢ýÈ ¦ÀÕÅ¢ÃÄ¢¨ÈìÌ §ÁÄ¡õ  
          ´ýÈ¡É Å¢ü¾¢ ±ýÈ ¸¡ÄÁ¡Ìõ 
          ¯¨ÃÂ¾¢ý §Áø ÃñÊ¨ÈìÌû Íñ§¼¡¾Ã¢.....”  
                                                -Varma Kannaadi-500   
           “§À¡¦ÁýÈ ¦ÀÕÅ¢Ãø ¦Á¡Æ¢ §Áø Å¢÷ò¾¢¸¡Äõ.”  
                                                                                              -  Adi Varma Sootcham-500 
“¦ÅøÖÅ¡÷ ¦ÀÕÅ¢ÃÖìÌ §ÁÄ¢¨È ´ýÈ¢ø Å¢Õò¾¢.”  
            - Varma Laada Soothiram-300  
Finger breadth below the nerukku varmam (5 fingers above from the tip of each toes) 
of great toe or placed at the interphalangeal joint of great toe. Virutthi varmam is located 2.5 
cms, above the tip of the big toe. 
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Symptoms:  
Damage to Viruthi kaalam causes Delirium, Swelling of legs, Faint.  
Uses: 
Strengthen the legs, used in emergency treatment.   
                                      7. ULLANKAI VELLAI VARMAM  
Synonyms: 
Vellai varmam                - Varma Kannadi-500 
Adi kuzhi                        - Varma Vidhi   
Munnoli varmam            - Varma Soothiram Panjikarana Pinnal 
Karunasakkira kaalam    - Varma Aani 
Kunju pichathi kaalam    - Varma Vilakkam  
Location:  
  "¾£ÃÓÚõ ¿Î¨¸ «¸§Á ¦Åû¨Ç Å÷Áõ" 
                                             -Adi Varma Sootcham 50 
  "§¾Ã¡É ¯ûÇí¨¸ ¦Åû¨Ç Å÷Áõ"  
                                            -Varma Kannadi  500
  “¸¡Ä¦ÁýÈ ¯ûÇí¨¸ ¿ÎÅ¢ø¾¡§É 
                 ¸ÊÉÁ¾¡õ ¸Õ½ºì¸¢Ã ¸¡Äõ À¡Õ." 
                                               -Varma Aani 100 
      It is located in the Centre of the palm. 
Sign and symptoms: 
Body pain, dull vision, fever, swelling and restriction in upper limbs. 
 Uses: 
 Strengthen the hip region, increases the memory power. 
8. ULLANKAAL VELLAI VARMAM 
Synonyms  
                     Adangal varmam       -  Varma Soothiram 1200   
    Kaal vellai varmam   -  Adivarma Sootcham 500  
    Allankaal varmam     -  Varma Viralalavu Nool 
        Adikkuzhi  varmam  -  Varma Vidhi 
       Vellai varmam          -  Varma Odivu Murivu Sara Soothiram 
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 Location:  
                     “¸£÷ò¾¢Â¡õ À¡¾Á¾¢ø ¦Åû¨Ç Å÷Áõ.” 
            - Varma Odivu Murivu Sara Soothiram -1200 
          “ÝðºÁ¼¡ ¦Åû¨ÇÂ¾¢ø «¼í¸ø Å÷Áõ.” 
                                                 - Varma Soothiram- 101 
              “À¨¼ÓÈ¢ò¾¡ý Å÷ÁòÐìÌ þÃñÎ Å¢ÃÖìÌì  
                   ¸£§Æ ¯ûÇí¸¡ø Å÷Áõ ..........” 
   -Varma Noolalavu Nool 
           “«ÅÉ¢¾É¢ø ¯ûÇí¸¡ø ¦Åû¨Ç Å÷Áõ.” 
                                                - Varma Peerangi-100  
           “«¸Á¡É ¯ûÇõ ¸¡ø ¦Åû¨Ç Å÷Áõ.” 
                                            -Adi Varma Sootcham-500 
In the centre of the plantar region.  
Symptoms:  
Fainting then death occurs. 
Retrieval techniques:  
 Massaging with medicated oil and taking head bath with oil cures eye diseases.  
Uses:  
 It cures giddiness, vomiting, faint, hysteria, convulsions and delirium.  
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MATERIALS AND METHODS 
  The Study on  Uthiravatha Suronitham was  carried out in the OPD and IPD  of the 
Sirappu Maruthuvam,National Instiute of Siddha. 
 According to the Agasthiyar Mani 4000 Ennum Vaithiya  Chinthamani Venbaa 4000 
Part -2 Pg no 37-38) and Theraiyar Vaagadam (Pg 64-65)], Amirtharasa Mathirai (Internal) 
and Suronitha Vatha Ennai (External) are the preparation indicated for  
Uthiravatha Suronitham. 
 STUDY DESIGN: 
A Pilot clinical trial 
STUDY PLACE:  
Ayothidoss Pandithar Hospital, National Institute of Siddha, Chennai-47. 
STUDY PERIOD:  
           12 months 
SAMPLE SIZE:  
           Totally 40 patients (20 OP + 20 IP). 10 IP Patients were treated with Varmam therapy 
along with internal and external  medicines and 10 IP and 20 OP patients were treated with 
internal and external medicines  only. 
TREATMENT: 
INTERNAL MEDICINE:    
     Drug: Amirtharasa Mathirai  
                   (Ref: Agathiyar Mani 4000 Ennum Vaithiya Chinthamani Venbaa 4000 
       Part -2 Pg No 37-38)  
Dosage :  130 mgs (twice a day) 
Duration: 48 days.  
EXTERNAL MEDICINE: 
      Drug: Suronitha Vatha Ennai. 
       [Ref: Theraiyar Vaagadam (Pg No 64-65)] 
Usage:  External use. 
STANDARD OPERATING PROCEDURE: 
Source of raw drugs: 
           The required raw drugs for preparation of “Amirtharasa Mathirai (Internal)”  and  
“Suronitha vatha ennai” (Ext.) were purchased from a well reputed country shop and the 
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purchased drugs were authenticated by  the H.O.D of the Medicinal botany at National 
Institute of Siddha and Chemistry department from CRI at Arumbakkam. 
PURIFICATION OF RAW DRUGS 
1. Purification of Rasam (Mercury) 
35 grams of Mercury was taken, grounded with brick powder and turmeric powder 
consecutively for about 1 hour and washed with water then mixed with 1.3 liters of  Kuppai 
meni juice (Acalypha indica) and was heated until the juice dried completely. 
                                                              Reference: Gunapadam Thadhu Jeeva Vaguppu(Pg No:245) 
2. Purification of Ganthagam (Sulphur) 
Sulphur was taken in an iron ladle along with cow’s butter and subjected to heat upto 
melting then it was poured into cow’s milk. This process was repeated for 9 more times. Then 
the sulphur was took out and dried to got it in purified form. 
                                                          - Reference : Gunapadam Thadhu Jeeva Vaguppu(Pg No:305)  
METHOD OF PREPARATION 
A. Internal Medicine: AMIRTHARASA  MATHIRAI  
Ingredients: 
·   Purified Rasam ( Mercury )                                -  70 grams 
·   Purified Gandagam (Sulphur)                           -  35 grams 
·   Avuri leaf juice (Indigofera tinctoria,Linn.)     - Quantity sufficient.           
Purified Mercury and purified Sulphur were grounded  to fine powder well by using 
Avuri charu, and then took in a mud plate subjected to heat,which was again  grounded well 
by using Avuri chru and made into pills (size –kundrimani 130mgs) 
           (Reference: Agathiyar Mani 4000 ennum Vaithiya Chinthamani  Venbaa 4000  
    part -2 Pg No 37-38)      
B. External Medicine: SURONITHA VATHA ENNAI 
Ingredients: 
1. Erukku  leaf ( Calotropis gigantean  (linn) R.B)  -  500grams 
2. Velai leaf (Cleome viscose. Linn.    -  500grams 
3. Notchi leaf  (Vitex negundo. Linn.)    -  500grams 
4. Puli leaf (Tamarindus indica.Linn.)   - 500grams 
5. Savuri leaf (Trichosanthes tricuspidata)   - 500grams 
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6. Goat’s milk                                                                         -       0.625ml 
7. Castor oil (Ricinus communis. Linn.)                                 -       0.625ml 
Method of Preparation:                                        
All the above said ingredients except goats milk and castor oil were first made into 
decotion form then mixed with Goats milk and castor oil, subjected to heat and then filtered 
in thylam form.  
         - Reference: Theraiyar  Vaagadam (Pg 64-65) 
Drug Storage: 
      The Amirtharasa  mathirai was  stored in clean and dry glass bottles and Suronitha 
vatha ennai was stored in clean and dry narrow mouthed bottles. 
Dispensing: 
       The internal medicine was distributed in pills form. External oil was distributed in 
Disposable pet bottles. 
VARMAM POINTS  APPLIED TO THE PATIENTS  
1. Mudichu 
2. Kavuli 
3. Chavvu 
4. Mozhi piralgai  
5. Komberi 
6. Viruthi 
7. Ullangal vellai 
8. Ullangai vellai 
The above points were stimulated  for the selected patients. 
SUBJECT SELECTION 
                 Patients reporting to NIS were subjected to screening by screening Proforma. After 
screening they were enrolled for the study fulfilling the inclusion criteria as said below. 
Inclusion Criteria 
· Age: 20- 60  years. 
· Sex: Both male and female. 
· Symmetrical joint involvement. 
· Arthritis of three or more joints. 
· Rheumatoid factor positive or negative. 
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· Morning stiffness. 
· Deformities like Swan neck deformity and Button hole deformity. 
· Swelling especially in the inter-phalangeal joint. 
· Patients willing for admission and stay in IPD or willing to attend OPD. 
· Patient willing to undergo Radiological investigation and for laboratory 
investigation. 
· Patient willing to sign the informed consent stating that he/she was consciously 
stick to the treatment during 48 days but could OPD out of the trial of his/her own 
conscious discretion.  
 Exclusion Criteria 
· Drug addicts 
· Pregnancy and lactation 
· Tubercular arthritis 
· Any other serious systemic illness 
· Osteoarthritis 
· Psoriatic arthritis 
· Gouty arthritis 
· HIV & AIDS 
Withdrawal Criteria 
· Intolerance to the drug and development of adverse reactions during drug trial. 
· Poor patient compliance and defaulters. 
· Patient turning unwilling to continue in the course of clinical trial. 
TESTS AND ASSESMENTS 
A. Clinical assessment  
B. Siddha investigation 
C. Laboratory investigations 
D. Radiological investigation 
A. CLINICAL ASSESMENT 
v Arthritis involving three or more joints 
v Symmetrical joint involvement  
v Morning stiffness 
v Anorexia 
v Spindle shaped appearance of fingers 
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v Rheumatoid nodules 
v Depression 
v Swelling of small joints of hands and foot. 
v Swan neck deformity 
v Button hole deformity 
B. SIDDHA SYSTEM EXAMINATION 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
C. ROUTINE INVESTIGATIONS 
BLOOD 
Hb 
Total WBC Count 
DC-  Polymorphs 
§ Lymphocytes  
§ Eosinophils  
§ Monocytes  
§ Basophils  
Total RBC count  
ESR 
  ½ Hr:              1 Hr: 
Blood sugar 
Fasting:           PP: 
Serum cholesterol 
URINE 
                  Albumin 
                  Sugar       (F)          (PP) 
            Deposits 
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Renal  function tests 
             Urea 
             Creatinine 
 Liver function tests 
              Serum Total bilirubin 
              Direct bilirubin 
              Indirect bilirubin 
              Serum Alkaline phosphatases 
              SGOT 
              SGPT 
C. SPECIFIC INVESTIGATIONS 
               CRP 
               RA factor  
               ASO titre  
RADIOLOGICAL INVESTIGATIONS 
                X- Ray of affected joints (AP and Lat view)  
DATA COLLECTION FORMS: 
    Required information were collected from each patient by using following forms. 
FORMS 
FORM I         : Screening and Selection Proforma  
FORM  II : History Taking Proforma  
FORM llI    : Clinical Assessment Proforma 
FORM  lV      : Laboratory Investigations Proforma 
FORM  V    : Informed Consent Form 
FORM VI  : Withdrawal Form  
FORM VII     : Adverse Reaction Report Form 
FORM VIII   : Patient Information Sheet 
FORM IX      : Dietary Advice Form  
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PATIENT SCREENING 
Inclusion/Exclusion 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
INFORMED CONSENT 
FORM 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
PHARMACOLOGICAL 
ASSESSMENT 
FURTHER MANAGEMENT 
OF ADVERSE DRUG 
REACTION 
WITH 
VARMAM 
WITHOUT 
VARMAM 
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STUDY ENROLLMENT  
Patients reporting at the OPD of NIS with the clinical symptoms of Uthira Vatha 
Suronitham were examined clinically. Based on the inclusion and exclusion criteria, they 
were enrolled for the study. 
The patients who were enrolled were informed about the study, trial drug, possible 
outcomes and the objectives of the study in their vernacular language. After ascertaining the 
patient’s willingness, informed consent were obtained in written form. 
All those patients were gave unique registration card in which patients Registration 
number of the study, Address, Phone number and Doctors phone number etc for their easy 
communications. 
Complete clinical history, complaints and duration, examination findings and 
laboratory findings were recorded in the prescribed Proformas. Patients were advised to took 
the trial drug and appropriate dietary advice. 
CONDUCT OF THE STUDY: 
Purgation with Agasthiyar Kuzhambu - 130 mgs early morning with Ginger juice  
gave for balancing the deranged mukkutram on the first day of the treatment.  
                                                                                  (Ref: Siddha formulary of India. Part- I) 
The next day onwards the trial drug Amirtharasa Mathirai (Internal) and Suronitha 
Vatha Ennai (External) were gave for 48 days. OPD patients were asked to visit the hospital 
once in 7 days. At each clinical visit clinical assessment was made and prognosis were noted. 
For IPD patients the clinical assessment were made daily in the Ward. 10 patients in IP ward 
were treaed by Varmam therapy along with the trial medicines. The results were compared at 
the end of the study. Laboratory investigations and radiological investigation were made on 
the first day and 48th day of the trial. At the end of the treatment, the patients were advised to 
visit the OPD for follow-up for futher 2 months for observing any recurrence. Defaulters 
were  not  allowed to continue and were withdrawn from the study. 
DATA ANALYSIS: 
After enrolling the patient in the study, a separate file were maintained for each and 
every patient and all forms and other information were kept in the file. The screening forms 
were filled separately. The data entry were monitored by the Head of the department and 
faculties of the concerned department. All collected datas were statistically analysed by 
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Senior Research Officer (Statistics) for logical errors and incompleteness of data to avoid any 
bias. No modification in the results was permitted for unbiased reports. Then final reports 
were generated. 
OUTCOME 
Assessment of pain was made by Universal pain assessment scale. Other clinical signs 
and symptoms were assessed by Gradation method. 
Laboratory investigations were  made at the end of the study. 
UNIVERSAL PAIN ASSESMENT SCALE: 
 
               
 
 
  
   Grade  0     :  No Pain 
               Grade 1 -3  :  Mild pain 
               Grade 4-6   :  Moderate pain 
               Grade 7-10 :  Severe pain 
                                                    - Ref: Clinical Manual for Nursing Practise.( National Institute  
                                                               of Health Warren Grant Magnuson Clinical Center )  
 Restricted movements is assessed by the following Gradation,  
Grade 1 – Able to perform normal duties 
Grade II – Moderate Restriction – Self care is possible 
Grade III – Marked restriction – Limited self care/some assistance required. 
Grade IV – Confined to bed or wheel chair 
ADVERSE EFFECTS/ SERIOUS EFFECTS MANAGEMENT:  
If the trial patient developed any adverse reaction, he/she was immediately informed 
to the Pharmaco-vigilance committee of NIS for further management.  
ETHICAL ISSUES 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments 
were used. 
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2. The patient were informed about the treatment and other procedures in his/her 
vernacular language. After received written consent only (language understandable to 
the patient) they were enrolled in the study.  
3. No other external or internal medicines were used, other than the trial drug during the 
trial period. There was no infringement on the rights of the patient.    
4. The data collected from the patient were kept confidential.  
5. Treatment were provided free of cost.  
6. If any serious adverse reactions occur during trial, the patients were gave alternative 
treatment at regular OPD of National Institute of Siddha.  
7. If the patient was not willing to continue the treatment, he/she was allowed to 
withdraw from the trial at any time.  
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OBSERVATIONS AND RESULTS 
Results of the study were observed with respect to the following criteria 
1. Gender distribution 
   2. Age distribution 
3. Socio-economic status 
4. Occupational distribution 
     5. Diet 
6. Thinai 
     7. Paruva Kaalam (Season) 
   8. Gunam 
   9. Body constitution 
   10.Naadi 
   11.Disturbances in Vali 
   12.Disturbances in Azhal 
13.Disturbances in Iyam 
14.Envagai thervugal 
   15.Neikkuri 
   16.Udal Thaathukkal 
   17.Kanmenthiriyam 
   18.Duration of Illness 
19.Mode of onset 
20.Clinical features 
21.Deformities 
22.Involvement of joints 
23.Results after treatment 
A.Reduction of pain 
B.Functional ability gradation 
C.Overall result after treatment 
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OBSERVATIONS AND RESULTS 
1. Gender distribution 
GENDER NUMBER OF PATIENTS PERCENTAGE % 
              Male 7 17 .5% 
              Female 33  82.5% 
              Total 40 100% 
 
 
 
 
 
Observation: 
           Among the 40 patients selected, the disease (R.A) was found to be higher in females 
(82.5%) and lower in males (17.5%). 
 
 
MALE
17.5%
FEMALE
82.5%
GENDER
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2. Age distribution 
AGE (YEARS) NUMBER OF PATIENTS PERCENTAGE % 
20  - 30 yrs 6 15% 
31 – 40 yrs 11 27.5% 
41 – 50 yrs 15 37.5% 
51 – 60 yrs 8 20% 
Total 40 100% 
 
 
 
 
Observation: 
15% of the affected patients came under the age group between 20-30 years. 27.5 % 
of the patients fell under the age group between 31-40 years, 37.5 % of them were between 
41-50 years and 20 % of them were between 51-60 years. 
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3. Socio-economic status 
 
 
Socio- economic status No. of cases Percentage % 
Low Income Group 21 52.5% 
Middle Income Group 14 35% 
High Income Group 5 12.5% 
Total 40 100% 
 
 
 
 
Observation: 
In my study the disease was found  Higher in the  Low income group 52.5%.  
Moderate in the Middle income group 35%.Lower in the High income group12.5%. 
 
Low
52.5%Middle
35%
High
12.5%
Socio ecnomic status
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4. Occupational distribution  
OCCUPATION NO. OF CASES 
PERCENTAGE 
% 
House maker 
 
31 77.5% 
Social worker 2  5% 
Tailor 1 2.5% 
Coolie 5 12.5% 
Lab Asst 1 2.5% 
Total 40 100% 
 
 
 
 
 
Observation: 
                   Among 40 cases, 31 cases (77.5%) were house maker, 2 cases (5% ) were social 
worker,1 Case ( 2.5%)  was Tailor, 5 Cases (12.5%) were cooli, 1 Case (2.5%) was Lab asst. 
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 5.Diet 
 
 
Diet No of cases Percentage % 
Vegetarian 8 20% 
Non vegetarian 32 80% 
Total 40 100% 
 
 
  
 
 
 
 
Observation: 
 Non vegetarian (80%) dieter were very higher than the vegetarian (20%) dieter. 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
Vegetarian Non vegetarian
Diet 20% 80%
20%
80%
Diet
57 
 
6. Thinai 
THINAI Number of patients 
Percentage 
% 
Kurinji - - 
Mullai - - 
Marutham 8 20% 
Neithal 32 80% 
Palai - - 
Total 40 100% 
 
 
Observation: 
 Amoug the 40 cases, 80% of cases were from Neithal and 20% of cases were from 
marutham nilam. 
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7. Paruva kaalam (Season)  
 
 
Observation: 
            Out of 40 cases 55% cases were took in Muthuvenil kaalam and 45% cases were took 
in Kaarkaalam. 
 
Kaarkaalam
45%
Mudhuvenil 
kaalam
55%
Season
SEASON Month and the 
year 
Number of the patients 
Percentage 
% 
Kaarkaalam 17th Aug-17th Oct 18 45% 
Koothirkaalam 18th  Oct-15th Dec - - 
Munpanikaalam 16th  Dec-12th Feb - - 
Pinpanikaalam 13th  Feb-13thApr - - 
Ilavenil kaalam 14th  Apr-16th June - - 
Mudhuvenil kaalam 17th June-16th Aug 22 55% 
Total  40 100% 
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8. Gunam 
GUNAM NUMBER OF PATIENTS 
PERCENTAGE 
 % 
Sathuvam 1 2.5% 
Rasatham 11 27.5% 
Thamasam 28 70% 
Total 40 100% 
 
 
 
 
Observation: 
          In Gunam 70% of cases had Thamo gunam, 27.5% of cases had Raso gunam, 2.5% of 
cases had Sathuva gunam. 
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9.Body constitution 
CONSTITUTION 
OF THE BODY 
NUMBER OF PATIENTS 
PERCENTAGE 
 % 
Vatha thegi - - 
Pitha thegi - - 
Kabam thegi - - 
Thontha thegi 40 100% 
 
 
 
Observation: 
              Out of 40 cases, all the cases (100%) were came under Thontha Thegi. 
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10. Naadi 
NAADI NUMBER OF 
PATIENTS 
PERCENTAGE  
% 
Vatha pitham 8 20% 
Pitha vatham 24 60% 
                      Pitha kabam 6 15% 
                      Kaba pitham 2 5% 
                      Total 40 100% 
 
 
 
 
 
Observation : 
                  Among 40 cases,Vatha pitha naadi was found in 8 cases (20%), Pitha vatha naadi 
was found in 24 cases (60%), Pitha kaba naadi was found in 6 cases (15%), Kaba pitha naadi 
was found in 2 cases (5%). 
 
vatha pitham Pitha vatham Pitha kabam Kaba pitham
20%
60%
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11.Disturbances in Vali 
VALI 
NUMBER OF  
PATIENTS 
PERCENTAGE  
% 
Praanan - - 
Abanan 15 37.5% 
Udhaanan - - 
Viyaanan 40 100% 
Samanan 40 100% 
Naagan - - 
Koormam - - 
Kirukaran - - 
Devathatan 2 5% 
Dhananjeyan - - 
 
 
 
Observation 
                       In Vatham, Viyaanan and Samanan were affected in all 40 cases (100%), 
Abanan was affected in 15 cases (37.5%) and Devathathan was affected in 2 cases (5%).  
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12. Disturbances in Azhal 
Azhal 
NUMBER OF  
PATIENTS 
PERCENTAGE  
% 
Analam 6 15% 
Saathagam 40 100% 
Ranjagam 20 50% 
Alosagam - - 
Prasagam 20 50% 
 
 
Observation 
       Among 40 cases, Saathagam was affected in all 40 cases (100%) , Ranjagam and 
Prasagam were affected in 20 cases(50%), Analam was affected in 6 cases (15%) . 
13. Disturbances in Iyam 
Only Santhigam was affected in all the 40 cases. 
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14. Envagai thervugal 
          
ENVAGAI THERVUGAL  NUMBER OF CASES  PERCENTAGE % 
Naa  20 50% 
Niram  - - 
Mozhi - - 
Vizhi  25 62.5% 
Sparisam 40 100% 
Malam 15 37.5% 
Moothiram - - 
 
 
 
Observation: 
                 In Envagai thervu , Sparisam was affected in 100% of patients where as Vizhi was 
affected in 62.5%, Naa was affected in 50% and Malam was affected in 37.5% of patients. 
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15. Neikkuri 
SPREADING PATTERN NUMBER OF  
PATIENTS 
PERCENTAGE 
% 
Aravena neendathu – Vatha neer 2 5% 
Aazhi pol paraviyadhu – Pitha neer 9 22.5% 
Muthothu nindrathu – Kaba neer 29 72.5% 
Total 40 100% 
 
 
 
 
 
Observation: 
               Among  40 cases,  Vatha neer was found in 2 cases (5%) , Pitha neer was found in  
9  cases (22.5%) and Kaba neer was  found in 29 cases (72.5%). 
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16.Udal Thaathukkal  
 
 
 
Observation: 
                      In my study Saram, Oon, Kozhuppu and Enbu were affected in all 40 cases and  
Senneer was affected in 5 cases only. 
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UDAL THAATHUKKAL NUMBER OF  
PATIENTS 
PERCENTAGE 
% 
Saaram 40 100 % 
Senneer 5 12.5% 
Oon 40 100% 
Kozhuppu 40 100% 
Enbu 40 100% 
Moolai - - 
Sukkilam/Suronitham - - 
 
67 
 
17. Kanmenthiriyam 
Kanmenthiriyam No of cases Percentage % 
Kai 40 100% 
Kaal 40 100% 
Vai -  - 
Eruvai 15 37.5% 
Karuvai - - 
 
 
 
 
Observation: 
                 In Kanmendrium Kai and Kaal were affected in 100% cases, Eruvai was affected 
in 37.5%  cases. 
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18.  Duration of Illness: 
DURATION OF ILLNESS NUMBER OF  CASES PERCENTAGE % 
Upto 6 months 4 10% 
6 months-1  year 7 17.5% 
1-2 years 8 20% 
2-3 years 7 17.5% 
3-10 years 14 35% 
Total 40 100% 
 
 
 
 
 
Observation: 
                In my study, about 35% cases had 3-10 yrs of duration, 17.5% cases had  2-3 yrs of 
duration, 20% cases had 1-2 yrs of duration,  17.5% cases had  6 mon – 1yr of duration and  
10% cases had 6 months of duration. 
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19. Mode of onset  
 
 
 
Observation : 
                    In my study  12% of cases had acute onset of illness, 30% of cases had subacute 
and  57.5% of cases had chronic onset of illness. 
 
 
Acute
12.5%
Subacute
30%
Chornic
57.5%
Mode of Onset
Mode  
of onset 
No of Cases 
 
Percentage % 
Acute 5 12.5% 
Subacute 12 30% 
Chronic 23 57.5% 
Total 40 100% 
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20. Clinical features: 
 
 
 
Observation: 
                      In my study, all 100% of cases had Pain, Swelling, Early morning stiffness, 
Warmth, Tenderness, and Restricted movements. 10% cases had Fever, 12.5% cases had 
Anorexia, 17.5% cases had Deformities, 57.5% cases had Polyarthralgia symptoms. 
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Clinical features  No. of cases  Percentage % 
Pain 40 100% 
Swelling 40 100% 
Morning stiffness 40 100% 
Tenderness 40 100% 
Warmth 40 100% 
Fever 4 10% 
Polyarthralgia 23 57.5% 
Deformity 7 17.5% 
Restricted movements 40 100% 
Anorexia 5 12.5% 
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21. Deformities: 
DEFORMITY NO OF CASES PERCENTAGE % 
   Spindle shaped fingers 7 17.5% 
   Swan neck 1 2.5% 
   Z Shaped - - 
   Ulnar deviation of hand 2 5% 
   Hallus Valgus 4 10% 
 
 
 
 
Observation: 
                    In my study,  17.5% of cases had Spindle shaped deformity,  10% of cases  had 
Hallus valgus derormity,  5% of cases had Ulnar deviation and 2.5% cases had Swan neck  
deformity. 
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22. Involvement of joints: 
Name of the joint No of cases Percentage % 
Cervical vertebrae 15 37.5% 
Elbow joint 34 85% 
Wrist joint 37 92.5% 
MCP joint 37 92.5% 
Knee joint 36 90% 
Ankle joint 35 87.5% 
 PIP joint 36 90% 
Hip joint 10 25% 
Lumbosacral joint 25 62.5% 
 
 
Observation:  
                     In my study, wrist and MCP joints were involved in 92.5% cases,  Knee and PIP 
joints were  involved  in 90% , Ankle joint was involved in 87.5% cases ,  Elbow joint was 
involved in 85% cases , Lumbosacral joint was  involved in 62.5% cases,  Cervical vertebrae 
were involved in 37.5% cases, and  Hip joint was involved in 25% cases. 
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RESULTS AFTER TREATMENT 
23 A. Reduction of pain 
Pain 
Before Treatment After Treatment 
No of patient Percentage 
% 
No of patient Percentage % 
  Severe Pain 27 67.5% 3 7.5% 
  Moderate Pain 11 27.5% 4 10% 
  Mild Pain 2 5% 24 60% 
  No Pain - - 9 22.5% 
  Total 40 100% 40 100% 
 
 
Observation: 
             In my study,Before treatment 67.5% of cases had Severe pain, 27.5% of cases had 
Moderate pain and 5% of cases  had Mild pain. 
 After treatment 7.5% of cases had Severe pain, 10% of cases had Moderate pain,  
60% of cases  had Mild pain and 22.5%of cases had No pain. 
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23.B. Functional ability gradation 
Grade 
No. of patients 
Before Treatment % After Treatment % 
Grade IV - - - - 
GradeIII 18 45% 3 7.5% 
GradeII 20 50% 9 22.5% 
GradeI 2 5% 28 70% 
Total 40 100% 40 100% 
Grade I -Fit for all activities 
Grade II -Mild restriction 
Grade III -Moderate restriction 
Grade IV  -Confined to chair or bed ridden 
 
Observation 
After the treatment among 40 cases, Restriction was reduced in 70% of cases,  Mild 
restriction was found in 22.5% of cases, Moderate restriction was found in 7.5% of cases. 
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23.C. Overall result after treatment  
Improvement No of cases Percentage % 
Good improvement 28 70% 
Moderate improvement 6 15% 
Mild improvement 3 7.5% 
No improvement 3 7.5% 
Total  40 100% 
 
 
Observation: 
         In my  study, 70% cases showed Good improvement, 15% cases showed  Moderate  
improvement, 7.5% cases showed Mild improvement and 7.5% cases showed No 
improvement. 
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STATISTICAL ANALYSIS 
TREATMENT WITH THE TRIAL DRUG 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical significance. 
Paired ‘t’ test was performed for determining the significance between before and after 
treatment. 
Paired Samples Statistics 
 
Mean N Std. Deviation Std. Error Mean 
 BEFORE 6.78 40 1.790 0.283 
AFTER 2.33 40 2.005 0.317 
 
The mean± standard deviation of pain score at before and after treatment were 6.78 ± 1.79 
and 2.33 ± 2 respectively which is statistically significant (t= 13.02 p<0.001). 
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STATISTICAL ANALYSIS  
VARMAM TREATMENT ALONG WITH THE TRIAL DRUG 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical significance. 
Paired ‘t’ test was performed for determining the significance between before and after 
treatment. 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 BEFORE 6.60 10 1.506 0.476 
AFTER 1.70 10 1.567 0.496 
 
 
Paired Samples Test 
 t df Sig. (2-tailed) 
Pair 1 BEFORE - AFTER 7.453 9 0.000 
 
The mean± standard deviation of pain score of patients who were subjected to Varmam 
before and after treatment were 6.60 ± 1.51 and 1.70 ± 1.56 respectively which is statistically 
significant (t= 7.45 p<0.001). 
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LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT   
OP- PATIENTS 
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30 
15 
18 
4 
82 
10 
10 
18 
46 
24 
22 
24 
32 
10 
18 
6 
74 
10 
38 
12 
78 
14 
8 
8 
22 
10 
38 
30 
4 
12 
6 
60 
36 
14 
12 
24 
56 
15 
12 
22 
6400 
8000 
9000 
12200 
6600 
8800 
9400 
6500 
9300 
9000 
5500 
8600 
9000 
5400 
6600 
5600 
9200 
8400 
12000 
8500 
6000 
8700 
7500 
10600 
7200 
10100 
9300 
7300 
9400 
8400 
5600 
7300 
6700 
4800 
6000 
5900 
9100 
9900 
10700 
10500 
79 
 
LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT   
                                                                              IP- PATIENTS 
S.No 
 
 
IP  No 
 
NAME 
 
AGE/
SEX 
 
Hb (gm/dl) 
TOTAL RBC 
COUNT(millo
n/                       
cu.mm) 
 
ESR 
(mm/hr) 
TOTAL WBC 
COUNT 
BT AT BT AT BT AT BT AT 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40 
4008 
4010 
4984 
4031 
4032 
5018 
4057 
5019 
4066 
4081 
4084 
4090 
4093 
4111 
4128 
4136 
4166 
4173 
5118 
4183 
Rani.H 
Latha.R 
Kaviyarasu.R 
Gowri.S 
Devi.V 
Deva prabhu.A 
Karpagam.D 
Ekambaram.V 
Durgadevi.D 
Padmini.K 
Padma.S 
Bhuvaneswari.N 
Boomadevi.S 
Mallini.M 
Manonmani.P 
Sundari.B 
Vanitha.R 
Rajammal.V 
Ragavel.S 
Jayanthi..S 
24/F 
40/F 
22/M 
46/F 
60/F 
23/M 
45/F 
43/M 
28/F 
39/F 
50/F 
55/F 
34/F 
38/F 
57/F 
55/F 
25/F 
46/F 
47/M 
52/F 
10.0 
12.8 
12.1 
11.3 
12.9 
15.6 
10.7 
15.2 
11.2 
13.5 
12.8 
12.7 
11.1 
14.3 
13.1 
13.7 
11.5 
11.9 
12.4 
11.9 
10.8 
13.9 
12.6 
11.3 
12.7 
13.7 
9.6 
13.6 
12.4 
12.2 
12.1 
10.4 
8.8 
11.7 
11.9 
11.7 
10.9 
12.1 
12.1 
12.1 
4.0 
4.6 
5.1 
3.8 
4.3 
5.3 
4.4 
5.0 
4.2 
5.1 
4.6 
4.4 
4.0 
4.9 
4.8 
4.6 
4.3 
4.3 
3.9 
4.4 
4.5 
5.0 
5.2 
4.1 
4.2 
5.0 
6.1 
5.1 
4.4 
5.2 
4.2 
4.3 
4.2 
4.9 
5.2 
4.5 
4.5 
4.2 
3.7 
4.5 
50 
48 
14 
8 
10 
40 
4 
6 
20 
12 
18 
18 
48 
4 
16 
18 
54 
8 
120 
48 
20 
14 
12 
38 
32 
4 
26 
4 
16 
12 
20 
20 
15 
16 
6 
12 
30 
10 
79 
24 
8300 
7200 
7800 
6800 
5600 
10700 
5500 
6900 
8000 
8600 
9900 
9200 
7100 
7000 
6700 
6800 
10700 
6900 
10600 
6800 
5300 
9300 
10100 
6500 
6500 
6700 
6100 
7200 
8100 
9000 
9500 
6900 
8300 
7200 
7900 
5700 
11100 
7100 
11200 
7100 
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LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT  
                                                   OP- PATIENTS 
 
S.N
o 
 
 
OP No 
 
NAME 
 
AGE/ 
SEX 
 
BLOOD 
GLUCOS
E 
(F) 
BLOOD 
GLUCOS
E 
(PP) 
TOTAL 
CHOLE 
STEROL  
UREA  
CREATI 
NINE 
BT AT BT AT BT AT 
 
BT AT BT AT 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
C76203 
C71572 
C39854 
C75158 
C82483 
C67099 
C65503 
C87033 
C66185 
B95982 
C47290 
C87533 
C53634 
C52991 
C48506 
C87390 
C73700 
B12088 
C67303 
C53286 
 
Vikneswari.A 
Maheshwari.D 
Lalitha.S 
Dhileepkumar.S 
Malarvizhi.N 
Valarmathi.K 
Jayanthi.G 
Revathy.M 
Gajalakshmi.A 
Shantha kumari.K 
Lakshmi maran.S 
Gnanavalli.P 
Bhavani.V 
Sangeetha.R 
Christilla.K 
Banumathy.R 
Kalavathy.C 
Selvakumar.R 
Ganesh.R 
Alamelu.M 
31/F 
50/F 
47/F 
50/M 
50/F 
51/F 
42/F 
50/F 
51/F 
31/F 
43/F 
40/F 
35/F 
34/F 
32/F 
38/F 
56/F 
41/M 
23/M 
50/F 
 
103 
94 
100 
94 
83 
78 
94 
86 
83 
83 
85 
82 
80 
92 
98 
103 
82 
90 
66 
100 
92 
72 
95 
99 
102 
91 
95 
109 
84 
96 
86 
88 
88 
84 
92 
102 
90 
92 
86 
108 
103 
103 
127 
136 
113 
138 
115 
101 
128 
104 
102 
108 
92 
110 
117 
123 
118 
100 
103 
126 
92 
116 
105 
126 
114 
108 
112 
121 
106 
102 
98 
106 
98 
92 
100 
119 
111 
111 
97 
135 
120 
171 
208 
148 
239 
160 
140 
206 
164 
151 
160 
215 
114 
117 
110 
161 
220 
172 
92 
254 
111 
151 
174 
140 
187 
148 
110 
183 
136 
205 
134 
190 
145 
118 
127 
207 
225 
165 
135 
305 
18 
25 
14 
19 
21 
23 
17 
16 
20 
14 
14 
19 
14 
14 
16 
15 
15 
14 
23 
14 
 
15 
19 
15 
15 
14 
19 
14 
14 
16 
15 
16 
17 
14 
14 
19 
14 
19 
20 
20 
15 
0.5 
0.7 
0.4 
0.5 
0.6 
0.6 
0.2 
0.5 
0.6 
0.4 
0.5 
0.7 
0.4 
0.5 
0.5 
0.6 
0.8 
0.4 
0.7 
0.4 
0.4 
0.5 
0.4 
0.4 
0.4 
0.5 
0.4 
0.5 
0.5 
0.5 
0.5 
0.5 
0.4 
0.4 
0.5 
0.4 
0.9 
0.5 
0.7 
0.6 
81 
 
LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT  
IP- PATIENTS  
 
 
S.No 
 
 
IP 
No 
 
NAME 
 
AGE/ 
SEX 
 
BLOOD 
GLUCOSE 
(F) 
BLOOD 
GLUCOSE 
(PP) 
TOTAL 
CHOLE 
STEROL  
UREA  
CREAT 
ININE 
BT AT BT AT BT AT 
 
BT AT BT AT 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40 
4008 
4010 
4984 
4031 
4032 
5018 
4057 
5019 
4066 
4081 
4084 
4090 
4093 
4111 
4128 
4136 
4166 
4173 
5118 
4183 
Rani.H 
Latha.R 
Kaviyarasu.R 
Gowri.S 
Devi.V 
Deva prabhu.A 
Karpagam.D 
Ekambaram.V 
Durgadevi.D 
Padmini.K 
Padma.S 
Bhuvaneswari.N 
Boomadevi.S 
Mallini.M 
Manonmani.P 
Sundari.B 
Vanitha.R 
Rajammal.V 
Ragavel.S 
Jayanthi..S 
24/F 
40/F 
22/M 
46/F 
60/F 
23/M 
45/F 
43/M 
28/F 
39/F 
50/F 
55/F 
34/F 
38/F 
57/F 
55/F 
25/F 
46/F 
47/M 
52/F 
85 
87 
84 
90 
97 
98 
107 
106 
86 
115 
105 
119 
88 
116 
89 
100 
94 
133 
84 
93 
91 
89 
70 
87 
84 
95 
98 
111 
90 
114 
102 
133 
90 
88 
113 
85 
99 
120 
90 
95 
110 
106 
101 
125 
108 
106 
140 
121 
107 
164 
134 
234 
102 
130 
108 
127 
125 
152 
129 
103 
108 
102 
93 
126 
100 
110 
135 
123 
111 
167 
125 
287 
110 
101 
176 
137 
120 
145 
121 
111 
209 
161 
114 
154 
154 
106 
162 
145 
169 
179 
168 
226 
149 
137 
216 
180 
105 
173 
140 
117 
144 
143 
95 
137 
209 
110 
140 
158 
165 
205 
180 
140 
177 
123 
222 
213 
125 
180 
157 
120 
16 
16 
14 
14 
25 
14 
20 
16 
24 
14 
17 
15 
16 
15 
23 
20 
14 
22  
14 
14 
 
14 
18 
14 
15 
25 
18 
16 
14 
29 
14 
19 
19 
14 
14 
14 
15 
15 
25 
16 
16 
0.5 
0.5 
0.4 
0.5 
0.7 
0.4 
0.6 
0.6 
0.7 
0.4 
0.5 
0.5 
0.5 
0.4 
0.6 
0.6 
0.4 
0.9 
0.4 
0.6 
0.4 
0.5 
0.4 
0.4 
0.9 
0.5 
0.5 
0.5 
0.9 
0.5 
0.4 
0.6 
0.5 
0.5 
0.4 
0.4 
0.5 
0.8 
0.5 
0.4 
82 
 
LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT  
                                              OP-PATIENTS 
 
S.No 
 
 
OP No 
 
NAME 
 
AGE/ 
SEX 
 
Total 
bilirubin 
SGOT SGPT 
Alkaline 
phosphatase 
BT AT BT AT BT AT BT AT 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
C76203 
C71572 
C39854 
C75158 
C82483 
C67099 
C65503 
C87033 
C66185 
B95982 
C47290 
C87533 
C53634 
C52991 
C48506 
C87390 
C73700 
B12088 
C67303 
C53286 
 
Vikneswari.A 
Maheshwari.D 
Lalitha.S 
Dhileep kumar.S 
Malarvizhi.N 
Valarmathi.K 
Jayanthi.G 
Revathy.M 
Gajalakshmi.A 
Shantha kumari.K 
Lakshmi maran.S 
Gnanavalli.P 
Bhavani.V 
Sangeetha.R 
Christilla.K 
Banumathy.R 
Kalavathy.C 
Selvakumar.R 
Ganesh.R 
Alamelu.M 
31/F 
50/F 
47/F 
50/M 
50/F 
51/F 
42/F 
50/F 
51/F 
31/F 
43/F 
40/F 
35/F 
34/F 
32/F 
38/F 
56/F 
41/M 
23/M 
50/F 
 
0.8 
0.5 
0.5 
0.6 
0.5 
0.5 
0.3 
0.6 
0.6 
0.7 
0.3 
0.4 
0.7 
0.5 
0.5 
0.4 
0.6 
0.5 
0.6 
0.5 
0.6 
0.5 
0.5 
0.5 
0.4 
0.6 
0.3 
0.4 
0.5 
0.4 
0.4 
0.5 
0.7 
0.6 
0.5 
0.5 
0.7 
0.9 
0.5 
0.6 
21 
26 
30 
29 
10 
13 
10 
27 
12 
10 
12 
20 
19 
28 
19 
17 
14 
16 
20 
12 
12 
14 
17 
14 
12 
13 
16 
14 
14 
15 
31 
13 
13 
22 
14 
12 
20 
20 
25 
14 
22 
51 
38 
30 
16 
14 
11 
29 
14 
8 
17 
21 
20 
15 
12 
18 
15 
17 
21 
14 
15 
16 
19 
16 
14 
15 
19 
16 
16 
17 
34 
15 
14 
25 
16 
14 
22 
21 
26 
16 
196 
170 
197 
156 
154 
130 
152 
191 
135 
186 
241 
196 
145 
198 
166 
176 
166 
180 
146 
138 
149 
181 
166 
166 
159 
179 
176 
140 
172 
185 
186 
194 
200 
156 
136 
151 
170 
190 
167 
189 
83 
 
LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT 
                                                       IP-PATIENTS 
 
                   
  
S.No 
 
 
IP  No 
 
NAME 
 
AGE/ 
SEX 
 
Total 
 bilirubin 
SGOT SGPT 
Alkaline 
phosphatase 
BT AT BT AT BT AT BT AT 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40 
4008 
4010 
4984 
4031 
4032 
5018 
4057 
5019 
4066 
4081 
4084 
4090 
4093 
4111 
4128 
4136 
4166 
4173 
5118 
4183 
Rani.H 
Latha.R 
Kaviyarasu.R 
Gowri.S 
Devi.V 
Deva prabhu.A 
Karpagam.D 
Ekambaram.V 
Durgadevi.D 
Padmini.K 
Padma.S 
Bhuvaneswari.N 
Boomadevi.S 
Mallini.M 
Manonmani.P 
Sundari.B 
Vanitha.R 
Rajammal.V 
Ragavel.S 
Jayanthi..S 
24/F 
40/F 
22/M 
46/F 
60/F 
23/M 
45/F 
43/M 
28/F 
39/F 
50/F 
55/F 
34/F 
38/F 
57/F 
55/F 
25/F 
46/F 
47/M 
52/F 
0.6 
0.4 
0.4 
0.5 
0.6 
0.2 
0.4 
0.5 
0.6 
0.4 
0.4 
0.6 
0.5 
0.5 
0.5 
0.5 
0.4 
0.4 
0.4 
0.6 
0.4 
0.4 
0.5 
0.4 
0.6 
0.2 
0.4 
0.4 
0.8 
0.5 
0.3 
0.5 
0.4 
0.5 
0.6 
0.7 
0.5 
0.6 
0.6 
0.4 
33 
16 
10 
16 
39 
13 
16 
26 
16 
41 
22 
11 
11 
17 
16 
13 
15 
38 
29 
13 
12 
15 
11 
26 
23 
13 
12 
16 
18 
42 
26 
10 
15 
16 
22 
18 
20 
32 
30 
15 
34 
18 
12 
18 
15 
14 
17 
20 
17 
20 
24 
12 
12 
19 
17 
14 
16 
28 
30 
15 
15 
17 
14 
29 
25 
15 
14 
18 
19 
31 
20 
11 
17 
18 
24 
20 
18 
29 
35 
18 
216 
199 
175 
194 
226 
152 
160 
159 
165 
198 
160 
136 
162 
150 
151 
145 
160 
190 
176 
183 
151 
135 
152 
197 
148 
166 
149 
154 
150 
193 
170 
166 
181 
172 
193 
166 
171 
210 
150 
200 
84 
 
     LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT 
                                                                         OP-PATIENTS 
    
S.No 
 
 
OP  No 
 
NAME 
 
AGE/ 
SEX 
 
Uric acid  Calcium  
 
Phosphorus 
BT AT BT AT BT AT 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
C76203 
C71572 
C39854 
C75158 
C82483 
C67099 
C65503 
C87033 
C66185 
B95982 
C47290 
C87533 
C53634 
C52991 
C48506 
C87390 
C73700 
B12088 
C67303 
C53286 
 
Vikneswari.A 
Maheshwari.D 
Lalitha.S 
Dhileep kumar.S 
Malarvizhi.N 
Valarmathi.K 
Jayanthi.G 
Revathy.M 
Gajalakshmi.A 
Shantha kumari.K 
Lakshmi maran.S 
Gnanavalli.P 
Bhavani.V 
Sangeetha.R 
Christilla.K 
Banumathy.R 
Kalavathy.C 
Selvakumar.R 
Ganesh.R 
Alamelu.M 
31/F 
50/F 
47/F 
50/M 
50/F 
51/F 
42/F 
50/F 
51/F 
31/F 
43/F 
40/F 
35/F 
34/F 
32/F 
38/F 
56/F 
41/M 
23/M 
50/F 
 
4.9 
6.3 
5.3 
5.4 
4.0 
3.2 
5.0 
4.2 
5.2 
5.0 
5.2 
5.5 
3.6 
4.3 
3.0 
4.2 
3.2 
6.9 
5.2 
3.4 
3.0 
6.1 
4.6 
4.4 
3.8 
3.1 
3.7 
4.9 
0.5 
3.0 
2.9 
5.1 
3.5 
3.0 
6.0 
3.4 
3.9 
7.1 
6.5 
3.9 
10.1 
9.5 
11.6 
10.2 
9.5 
10.3 
10.0 
10.0 
10.6 
10.0 
10.6 
10.6 
10.5 
10.6 
10.1 
11.2 
10.9 
10.2 
10.9 
9.9 
10.7 
10.0 
11.0 
10.4 
9.6 
10.6 
9.8 
10.5 
10.6 
10.8 
11.0 
10.1 
10.9 
10.1 
10.8 
10.0 
10.5 
10.8 
9.6 
8.7 
2.3 
2.5 
3.2 
2.8 
2.5 
3.1 
3.0 
3.0 
3.1 
3.4 
3.0 
3.4 
3.5 
3.4 
3.9 
3.1 
3.2 
3.2 
3.0 
2.8 
3.0 
2.9 
2.9 
3.0 
3.0 
2.9 
2.7 
3.1 
3.0 
2.9 
3.2 
2.2 
3.1 
3.0 
3.1 
2.7 
3.5 
4.0 
3.0 
3.0 
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 LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT  
 IP-PATIENTS 
S.No 
 
 
IP  No 
 
NAME 
 
AGE/ 
SEX 
 
Uric acid  Calcium  
 
Phosphorus 
BT AT BT AT BT AT 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40 
4008 
4010 
4984 
4031 
4032 
5018 
4057 
5019 
4066 
4081 
4084 
4090 
4093 
4111 
4128 
4136 
4166 
4173 
5118 
4183 
Rani.H 
Latha.R 
Kaviyarasu.R 
Gowri.S 
Devi.V 
Deva prabhu.A 
Karpagam.D 
Ekambaram.V 
Durgadevi.D 
Padmini.K 
Padma.S 
Bhuvaneswari.N 
Boomadevi.S 
Mallini.M 
Manonmani.P 
Sundari.B 
Vanitha.R 
Rajammal.V 
Ragavel.S 
Jayanthi..S 
24/F 
40/F 
22/M 
46/F 
60/F 
23/M 
45/F 
43/M 
28/F 
39/F 
50/F 
55/F 
34/F 
38/F 
57/F 
55/F 
25/F 
46/F 
47/M 
52/F 
5.1 
5.2 
4.9 
4.2 
4.5 
6.0 
3.7 
4.2 
6.4 
7.5 
4.0 
5.2 
4.1 
3.4 
4.8 
5.3 
3.7 
3.2 
4.2 
3.0 
3.0 
4.5 
3.6 
3.0 
6.6 
5.6 
4.0 
5.0 
6.1 
6.3 
3.9 
3.0 
3.1 
3.4 
4.3 
5.2 
3.9 
3.9 
4.5 
3.7 
10.0 
10.6 
11.6 
10.6 
10.2 
10.4 
10.9 
10.1 
10.2 
11.5 
10.6 
10.5 
10.1 
10.0 
11.0 
10.1 
9.9 
10.5 
10.2 
10.7 
10.7 
10.6 
10.1 
10.6 
10.1 
10.1 
10.6 
11.0 
10.8 
10.5 
10.8 
11.0 
10.7 
9.8 
10.5 
10.0 
10.2 
10.1 
10.1 
10.2 
3.0 
2.9 
3.0 
2.9 
3.1 
3.0 
3.9 
2.9 
3.0 
3.2 
3.0 
3.1 
3.7 
3.0 
3.0 
3.0 
2.8 
3.1 
4.0 
3.0 
2.9 
3.2 
2.9 
3.2 
2.7 
2.7 
3.1 
3.2 
3.2 
3.2 
2.9 
3.2 
3.2 
3.1 
3.1 
2.7 
3.1 
2.9 
3.9 
3.5 
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LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT  
OP-PATIENTS 
S.No 
 
 
OP  No 
 
NAME 
 
AGE/ 
SEX 
 
RA factor  ASO titre 
 
CRP 
BT AT BT AT BT AT 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
C76203 
C71572 
C39854 
C75158 
C82483 
C67099 
C65503 
C87033 
C66185 
B95982 
C47290 
C87533 
C53634 
C52991 
C48506 
C87390 
C73700 
B12088 
C67303 
C53286 
 
Vikneswari.A 
Maheshwari.D 
Lalitha.S 
Dhileep kumar.S 
Malarvizhi.N 
Valarmathi.K 
Jayanthi.G 
Revathy.M 
Gajalakshmi.A 
Shantha kumari.K 
Lakshmi maran.S 
Gnanavalli.P 
Bhavani.V 
Sangeetha.R 
Christilla.K 
Banumathy.R 
Kalavathy.C 
Selvakumar.R 
Ganesh.R 
Alamelu.M 
31/F 
50/F 
47/F 
50/M 
50/F 
51/F 
42/F 
50/F 
51/F 
31/F 
43/F 
40/F 
35/F 
34/F 
32/F 
38/F 
56/F 
41/M 
23/M 
50/F 
 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
+ve 
+ve 
+ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
+ve 
+ve 
-ve 
-ve 
 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
+ve 
+ve 
+ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
-ve 
 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
 
-ve 
-ve 
-ve 
+ve 
+ve 
+ve 
+ve 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
-ve 
+ve 
-ve 
-ve 
+ve 
+ve 
-ve 
 
+ve 
-ve 
-ve 
+ve 
+ve 
+ve 
+ve 
-ve 
+ve 
-ve 
+ve 
+ve 
-ve 
-ve 
+ve 
-ve 
-ve 
-ve 
-ve 
+ve 
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                    LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT 
                                                                                   IP-PATIENTS 
S.No 
 
 
IP  No 
 
NAME 
 
AGE/ 
SEX 
 
RA factor  ASO titre 
 
CRP 
BT AT BT AT BT AT 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40 
4008 
4010 
4984 
4031 
4032 
5018 
4057 
5019 
4066 
4081 
4084 
4090 
4093 
4111 
4128 
4136 
4166 
4173 
5118 
4183 
Rani.H 
Latha.R 
Kaviyarasu.R 
Gowri.S 
Devi.V 
Deva prabhu.A 
Karpagam.D 
Ekambaram.V 
Durgadevi.D 
Padmini.K 
Padma.S 
Bhuvaneswari.N 
Boomadevi.S 
Mallini.M 
Manonmani.P 
Sundari.B 
Vanitha.R 
Rajammal.V 
Ragavel.S 
Jayanthi..S 
24/F 
40/F 
22/M 
46/F 
60/F 
23/M 
45/F 
43/M 
28/F 
39/F 
50/F 
55/F 
34/F 
38/F 
57/F 
55/F 
25/F 
46/F 
47/M 
52/F 
+ve 
+ve 
-ve 
+ve 
+ve 
+ve 
+ve 
-ve 
-ve 
+ve 
+ve 
-ve 
+ve 
-ve 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
 
+ve 
+ve 
-ve 
+ve 
+ve 
-ve 
+ve 
-ve 
-ve 
+ve 
+ve 
-ve 
+ve 
-ve 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
 
-ve 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
 
+ve 
+ve 
+ve 
+ve 
-ve 
-ve 
-ve 
-ve 
+ve 
+ve 
+ve 
+ve 
+ve 
-ve 
-ve 
+ve 
+ve 
+ve 
+ve 
-ve 
 
+ve 
+ve 
+ve 
+ve 
-ve 
-ve 
-ve 
-ve 
+ve 
-ve 
+ve 
-ve 
+ve 
+ve 
-ve 
+ve 
-ve 
+ve 
+ve 
-ve 
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                      LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT 
                                                                                  OP-PATIENTS 
S. 
No 
 
 
OP No 
 
NAME 
 
AGE/ 
SEX 
 
URINE 
SUGER 
(F) 
URINE 
SUGER 
(PP) 
ALBUMIN 
DEPOSITS 
Epithelial 
cells Pus cells 
BT AT BT AT BT AT BT AT BT AT 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
C76203 
C71572 
C39854 
C75158 
C82483 
C67099 
C65503 
C87033 
C66185 
B95982 
C47290 
C87533 
C53634 
C52991 
C48506 
C87390 
C73700 
B12088 
C67303 
C53286 
 
Vikneswari.A 
Maheshwari.D 
Lalitha.S 
Dhileep kumar.S 
Malarvizhi.N 
Valarmathi.K 
Jayanthi.G 
Revathy.M 
Gajalakshmi.A 
Shantha kumari.K 
Lakshmi maran.S 
Gnanavalli.P 
Bhavani.V 
Sangeetha.R 
Christilla.K 
Banumathy.R 
Kalavathy.C 
Selvakumar.R 
Ganesh.R 
Alamelu.M 
31/F 
50/F 
47/F 
50/M 
50/F 
51/F 
42/F 
50/F 
51/F 
31/F 
43/F 
40/F 
35/F 
34/F 
32/F 
38/F 
56/F 
41/M 
23/M 
50/F 
 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
2-4 
4-5 
2-4 
2-4 
6-8 
3-5 
1-2 
3-5 
2-4 
3-5 
4-5 
2-4 
1-2 
2-3 
2-4 
8-10 
2-4 
1-2 
4-6 
2-4 
2-4 
4-5 
2-4 
2-4 
2-4 
2-3 
1-2 
3-5 
2-4 
1-2 
4-5 
1-2 
2-4 
2-3 
0-1 
1-2 
1-2 
1-2 
8-10 
2-4 
2-4 
2-4 
2-4 
1-2 
4-6 
3-5 
2-4 
3-5 
2-4 
3-5 
4-5 
1-3 
1-2 
2-4 
1-2 
4-6 
2-4 
1-2 
4-6 
2-4 
2-4 
2-4 
2-3 
1-2 
2-4 
2-3 
2-4 
2-4 
2-4 
0-1 
3-4 
2-4 
2-4 
2-4 
1-2 
2-3 
1-2 
1-2 
8-10 
2-4 
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LABARATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT 
IP-PATIENTS   
 
S. 
No 
 
 
IP No 
 
NAME 
 
AGE/ 
SEX 
 
URINE 
SUGER 
(F) 
URINE 
SUGER 
(PP) 
ALBUMI
N 
DEPOSITS 
 
Epithelial 
cells 
Pus cells 
BT AT BT AT BT AT BT AT BT AT 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40 
4008 
4010 
4984 
4031 
4032 
5018 
4057 
5019 
4066 
4081 
4084 
4090 
4093 
4111 
4128 
4136 
4166 
4173 
5118 
4183 
Rani.H 
Latha.R 
Kaviyarasu.R 
Gowri.S 
Devi.V 
Deva prabhu.A 
Karpagam.D 
Ekambaram.V 
Durgadevi.D 
Padmini.K 
Padma.S 
Bhuvaneswari.N 
Boomadevi.S 
Mallini.M 
Manonmani.P 
Sundari.B 
Vanitha.R 
Rajammal.V 
Ragavel.S 
Jayanthi..S 
24/F 
40/F 
22/M 
46/F 
60/F 
23/M 
45/F 
43/M 
28/F 
39/F 
50/F 
55/F 
34/F 
38/F 
57/F 
55/F 
25/F 
46/F 
47/M 
52/F 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
nil 
 
2-4 
2-4 
1-2 
2-4 
2-5 
3-5 
2-4 
4-5 
1-2 
2-4 
3-6 
1-2 
2-5 
8-10 
3-4 
3-5 
3-6 
4-5 
5-6 
1-2 
2-4 
2-3 
1-2 
2-3 
2-4 
4-5 
2-3 
2-4 
1-2 
2-4 
1-2 
2-3 
5-8 
3-5 
2-3 
2-4 
2-3 
2-4 
1-2 
2-3 
 
2-4 
2-4 
1-2 
1-2 
2-4 
4-5 
2-4 
2-3 
2-4 
1-3 
3-6 
1-2 
2-4 
6-8 
2-6 
3-6 
2-6 
5-7 
8-10 
1-2 
2-4 
4-6 
1-2 
1-2 
2-3 
1-2 
1-2 
2-4 
2-4 
2-4 
1-2 
2-2 
4-5 
2-4 
1-2 
3-4 
4-5 
6-7 
1-2 
1-2 
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CLINICAL IMPROVEMENT - OP CASES 
 
S. 
No O.P NO NAME 
AGE/ 
SEX 
DOA 
DURATION 
OF 
ILLNESS 
DAYS RESULT 
1. C76203 Vikneswari.A 31/F 24.7.12 7 Month 48 Good 
2. C71572 Maheshwari.D 50/F 24.7.12 9 Month 48 Good 
3. C39854 Lalitha.S 47/F 26.7.12 8 Month 48 Good 
4. C75158 Dhileep kumar.S 50/M 27.7.12 5 Month 48 Good 
5. C82483 Malarvizhi.N 50/F 27.7.12 2 Years 48 Good 
6. C67099 Valarmathi.K 51/F 27.7.12 7 Years 48 Good 
7. C65503 Jayanthi.G 42/F 28.7.12 5 Years 48 Good 
8. C87033 Revathy.M 50/F 29.7.12 4 Years 48 Good 
9. C66185 Gajalakshmi.A 51/F 1.8.12 2 Years 48 Moderate 
10. B95982 Shantha kumari.K 31/F 1.8.12 4 Years 48 Good 
11. C47290 Lakshmi maran.S 43/F 1.8.12 4 Years 48 Good 
12. C87533 Gnanavalli.P 40/F 1.8.12 4 Years 48 Good 
13. C53634 Bhavani.V 35/F 1.8.12 5 Years 48 Good 
14. C52991 Sangeetha.R 34/F 2.8.12 10 Years 48 Mild 
15. C48506 Christilla.K 32/F 5.8.12 3 Years 48 Good 
16. C87390 Banumathy.R 38/F 6.8.12 4 Years 48 Good 
17. C73700 Kalavathy.C 56/F 6.8.12 4 Years 48 Good 
18. B12088 Selvakumar.R 41/M 7.8.12 3 Years 48 Moderate 
19. C67303 Ganesh.R 23/M 7.8.12 1 Year 48 Moderate 
20. C53286 Alamelu.M 50/F 10.8.12 9 Years 48 Good 
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CLINICAL IMPROVEMENT - IP CASES 
 
 
S. 
No 
I.P 
NO NAME 
AGE/ 
SEX DOA 
DURATION 
OF ILLNESS DAYS RESULT 
21 4008 Rani.H 24/F 27.7.12 8 Months 48 Mild 
22 4010 Latha.R 40/F 28.7.12 1 Year 48 Good 
23 4984 Kaviyarasu.R 22/M 30.7.12 7 Months 48 Moderate 
24 4031 Gowri.S 46/F 1.8.12 5 Years 48 No 
25 4032 Devi.V 60/F 1.8.12 6 Years 48 Moderate 
26 5018 Deva prabhu.A 23/M 8.8.12 1 Year 48 Good 
27 4057 Karpagam.D 45/F 9.8.12 7 Months 48 Good 
28 5019 Ekambaram.V 43/M 9.8.12 10 Years 48 Good 
29 4066 Durgadevi.D 28/F 11.8.12 3 Years 48 Good 
30 4081 Padmini.K 39/F 17.8.12 2 Years 48 Good 
31 4084 Padma.S 50/F 18.8.12 8 Months 48 No 
32 4090 Bhuvaneswari.N 55/F 21.8.12 3 Months 48 Good 
33 4093 Boomadevi.S 34/F 21.8.12 4 Years 48 Good 
34 4111 Mallini.M 38/F 24.8.12 1 year 48 Good 
35 4128 Manonmani.P 57/F 28.8.12 1 year 48 Good 
36 4136 Sundari.B 55/F 29.8.12 4 Years 48 Good 
37 4166 Vanitha.R 25/F 8.9.12 1 Year 48 Good 
38 4173 Rajammal.V 46/F 10.9.12 2 Months 48 No 
39 5118 Ragavel.S 47/M 11.9.12 3 Months 48 Moderate 
40 4183 Jayanthi..S 52/F 13.9.12 1 Year 48 Mild 
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PAIN SCORE – OP PATIENTS 
S.No OP No NAME 
AGE/ 
SEX 
 PAIN SCORE GRADING 
BT AT BT AT 
1. C76203 Vikneswari.A 31/F 8 0 G3 G1 
2. C71572 Maheshwari.D 50/F 7 0 G2 G1 
3. C39854 Lalitha.S 47/F 5 1 G3 G1 
4. C75158 Dhileep kumar.S 50/M 8 2 G2 G1 
5. C82483 Malarvizhi.N 50/F 6 0 G2 G1 
6. C67099 Valarmathi.K 51/F 8 3 G3 G1 
7. C65503 Jayanthi.G 42/F 8 2 G2 G1 
8. C87033 Revathy.M 50/F 5 2 G3 G1 
9. C66185 Gajalakshmi.A 51/F 7 5 G2 G2 
10. B95982 Shantha kumari.K 31/F 4 2 G2 G1 
11. C47290 Lakshmi maran.S 43/F 8 3 G3 G2 
12. C87533 Gnanavalli.P 40/F 3 1 G2 G1 
13. C53634 Bhavani.V 35/F 4 0 G3 G1 
14. C52991 Sangeetha.R 34/F 8 2 G3 G2 
15. C48506 Christilla.K 32/F 7 3 G2 G2 
16. C87390 Banumathy.R 38/F 9 2 G1 G1 
17. C73700 Kalavathy.C 56/F 7 3 G2 G1 
18. B12088 Selvakumar.R 41/M 8 5 G3 G2 
19. C67303 Ganesh.R 23/M 5 2 G2 G1 
20. C53286 Alamelu.M 50/F 9 0 G2 G1 
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PAIN SCORE – IP PATIENTS 
S.No IP No NAME 
AGE/ 
SEX 
 PAIN SCORE GRADING 
BT AT BT AT 
21 4008 Rani.H 24/F 7 3 G3 G2 
22 4010 Latha.R 40/F 8 0 G2 G1 
23 4984 Kaviyarasu.R 22/M 9 4 G3 G1 
24 4031 Gowri.S 46/F 9 8 G3 G3 
25 4032 Devi.V 60/F 7 4 G2 G1 
26 5018 Deva prabhu.A 23/M 7 3 G3 G1 
27 4057 Karpagam.D 45/F 8 0 G2 G1 
28 5019 Ekambaram.V 43/M 7 2 G3 G1 
29 4066 Durgadevi.D 28/F 5 1 G2 G1 
30 4081 Padmini.K 39/F 6 3 G2 G2 
31 4084 Padma.S 50/F 8 7 G3 G3 
32 4090 Bhuvaneswari.N 55/F 7 2 G2 G1 
33 4093 Boomadevi.S 34/F 5 3 G1 G1 
34 4111 Mallini.M 38/F 8 1 G2 G2 
35 4128 Manonmani.P 57/F 4 0 G2 G1 
36 4136 Sundari.B 55/F 2 0 G3 G1 
37 4166 Vanitha.R 25/F 8 2 G3 G1 
38 4173 Rajammal.V 46/F 8 7 G3 G3 
39 5118 Ragavel.S 47/M 9 2 G3 G2 
40 4183 Jayanthi..S 52/F 5 3 G2 G1 
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VARMAM TREATMENT ALONG WITH THE TRIAL DRUG 
IP PATIENTS 
S.No IP No NAME 
AGE/ 
SEX 
 PAIN 
SCORE GRADING RESULT 
BT AT BT AT 
1. 4010 Latha.R 40/F 8 0 G3 G1 Good 
2. 4057 Karpagam.D 45/F 8 0 G2 G1 Good 
3. 5019 Ekambaram.V 43/M 7 2 G3 G1 Good 
4. 4066 Durgadevi.D 28/F 5 1 G2 G1 Good 
5. 4081 Padmini.K 39/F 6 3 G2 G1 Good 
6. 4090 Bhuvaneswari.N 55/F 7 2 G3 G1 Good 
7. 4111 Mallini.M 38/F 8 1 G2 G1 Good 
8. 4128 Manonmani.P 57/F 4 0 G3 G1 Good 
9. 4136 Sundari.B 55/F 2 0 G2 G2 Good 
10. 4166 Vanitha.R 25/F 8 2 G2 G1 Good 
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     BIO -CHEMICAL ANALYSIS OF AMIRTHARASA MATHIRAI ANALYSED AT  
                                       NATIONAL INSTITUTE OF SIDDHA 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of sample Black red  in colour  
2. Solubility: 
a. A little (500mg) of the sample is         
shaken well with distilled water. 
b. A little (500mg) of the sample is shaken 
well with con. HCl/ Con. H2So4 
 
Sparingly soluble 
 
 
Presence of 
Silicate 
3. Action of Heat: 
        A small amount (500mg) of the sample 
is taken in a dry test tube and heated gently 
at first and then strong. 
 
White fumes   
evolved 
 
Presence of 
Carbonate 
 
4. Flame Test: 
        A small amount (500mg) of the sample 
is made into a paste with con. HCl in a 
watch glass and introduced into non-
luminous part of the Bunsen flame. 
 No Bluish green 
flame appeared. 
Absence of 
Copper 
5. Ash Tests:  
        A filter paper is soaked into a mixture 
of sample and dil. cobalt nitrate solution 
and introduced into the Bunsen flame and 
ignited 
 No Yellow colour 
flame 
Absence  of 
sodium 
Preparation of Extract:   
       5gm of Amirtharasa mathirai  is weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 minutes. 
Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml with distilled 
water. 
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S.No EXPERIMENT OBSERVATION INFERENCE 
 I. Test For Acid Radicals   
1. Test For Sulphate: 
       2ml of the above prepared 
extract is taken in a test tube to this 
added 2ml of 4% dil ammonium 
oxalate solution. 
No Cloudy 
appearance present 
Absent of  Sulphate 
2. Test For Chloride: 
      2ml of the above prepared 
extracts is added with 2ml of  
dil-HCl is added until the 
effervescence ceases off.. 
Cloudy appearance 
present 
Presence of Chloride 
3. Test For Phosphate: 
       2ml of the extract is treated 
with 2ml of dil.ammonium 
molybdate solution and 2ml of 
con.HNo3 
No cloudy yellow 
appearance present 
Absent of Phosphate 
4.  Test For Carbonate: 
       2ml of the extract is treated 
with 2mldil. magnesium sulphate 
solution 
No Cloudy 
appearance present 
Absent of Carbonate 
C Test For Nitrate: 
      1gm of the substance is heated 
with copper turning and con.H2So4 
and viewed the test tube vertically 
down. 
No Brown gas is 
evolved 
Absence of Nitrate 
6. Test For Sulphide: 
     1gm of the substance is treated 
with 2ml of con. HCL 
Rotten Egg Smelling 
gas evolved 
Presence of Sulphide 
7. Test For Fluoride & Oxalate: 
     2ml of extract is added with 2ml 
of dil. Acetic acid & 2ml dil. 
calcium chloride solution & heated. 
No Cloudy         
appearance 
Absence of fluoride 
and oxalate 
97 
 
8. Test For Nitrite: 
     3drops of the extract is placed 
on a filter paper, on that-2 drops of 
dil.acetic acid and 2 drops of dil. 
Benzidine solution is placed. 
No Characteristic 
changes 
Absence of Nitrite 
9. Test For Borate: 
      2 Pinches (50mg) of the 
substance is made into paste by 
using dil.sulphuric acid and alcohol 
(95%) and introduced into the blue 
flame. 
 
 
Bluish green colour 
flame not appeared 
 
 
Absence of borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
       2ml of the extract is added 
with 2ml of dil.potassium iodine 
solution. 
NoYellow Precipitate 
is obtained. 
Absence of Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance is 
made into paste with con. HClin a 
watch glass and introduced into the 
non-luminuous part of the flame. 
No Blue colour flame 
No Blue colour 
precipitate formed. 
Absence of copper 
3. Test For Aluminium: 
        To the 2ml of extract 
dil.sodium hydroxide is added in 5 
drops to excess. 
No characteristic 
changes 
Absence of aluminium 
4. Test For Iron: 
a.To the 2ml of extract add 2ml of 
dil.ammonium solution 
b.To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of 
con HNo3 is added 
 
 
Red colour appeared 
 
Presence of Iron 
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5. Test For Zinc:  
      To 2ml of the extract 
dil.sodium hydroxide solution is 
added in 5 drops to excess and 
dil.ammonium chloride is added.  
 
White precipitate is   
not formed 
 Absence of Zinc 
6. Test For Calcium:  
      2ml of the extract is added with 
2ml of 4% dil.ammonium oxalate 
solution  
No Cloudy 
appearance and white 
precipitate is 
obtained 
 Absence of calcium 
7. Test For Magnesium:  
      To 2ml of extract dil.sodium 
hydroxide solution is added in 
drops to excess. 
White precipitate is  
obtained 
 Presence of 
Magnesium 
8. Test For Ammonium: 
       To 2ml of extract 1 ml of 
Nessler's reagent and excess of 
dil.sodium hydroxide solution are 
added. 
  No Brown colour 
appeared 
Absence of ammonium 
9. Test For Potassium:  
       A pinch (25mg) of substance is 
treated of with 2ml of dil.sodium 
nitrite solution and then treated 
with 2ml of dil.cobalt nitrate in 
30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate is 
obtained. 
 
Absence of Potassium 
10. Test For Sodium: 
        2 pinches (50mg) of the 
substance is made into paste by 
using HCl and introduced into the 
blue flame of Bunsen burner. 
  
Yellow colour flame 
appeared 
  
Presence  of Sodium 
11. Test For Mercury:  
     2ml of the extract is treated with 
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2ml of dil.sodium hydroxide 
solution.  
No yellow precipitate 
is obtained 
Absence of Mercury 
12. Test For Arsenic:  
      2ml of the extract is treated 
with 2ml of dil.sodium hydroxide 
solution. 
No brownish red 
precipitate is 
obtained 
Absence of Arsenic 
 III. Miscellaneous   
1.
  
Test For Starch:  
2ml of extract is treated with weak 
dil.Iodine solution  
No Blue colour 
developed 
Absence of starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
added 8 to 10 drops of the extract 
and again boil it for 2 minutes. The 
colour changes are noted. 
  
 
No Brick red colour  
is developed 
 
 
Absence of reducing 
sugar 
3.
  
Test For The Alkaloids: 
a)2ml of the extract is treated with    
2ml of dil.potassium lodide 
solution. 
b)  2ml of the extract is treated with 
2ml of dil.picric acid. 
c)  2ml of the extract is treated with 
2ml of dil.phosphotungstic acid. 
 
Red colour 
developed 
 Yellow colour 
developed 
White precipitate 
developed 
 
 
 
Presence of Alkaloid 
4.
  
Test For Tannic Acid:  
      2ml of extract is treated with 
2ml of dil.ferric chloride solution  
 
  
No black precipitate 
is obtained 
 
Absence of Tannic acid 
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5.
  
Test For Unsaturated 
Compound: 
      To the 2ml of extract 2ml of 
dil.Potassium  permanganate 
solution is added.  
 
Potassium 
permanganate is not 
decolourised 
 
Absence of unsaturated 
compound  
6.
  
Test For Amino Acid: 
    2 drops of the extract is placed 
on a filter paper and dried well. 
20ml of  Biurette reagent is added. 
 
No Violet colour 
developed 
 
Absenc of amino acids 
7. Test For Type Of Compound: 
    2ml of the extract is treated with 
2 ml of dil.ferric chloride solution.  
No green colour 
Developed 
 
No red colour 
developed 
 
No violet colour 
developed 
No blue colour 
developed 
Absence of oxy 
quinole pinephrine and 
pyro catechol. 
Anti pyrine, Aliphatic 
amino acids and 
meconic acid are 
absent  
Apomorphine 
salicylate and 
Resorcinol are absent 
Morphine, Phenol 
cresol and 
hydrouinoneare absent 
 
Preliminary Qualitative Phyto chemical tests procedure and interpretation of results 
S.NO CONSITUENTS INFERENCE 
1. Silicate Present 
2. Carbonate Present 
3. Chloride Present 
4. Sulphide Present 
5. Iron Present 
6. Alkaloids Present 
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7. Copper Absent 
8. Sodium Absent 
9. Sulphate Absent 
10. Phospate Absent 
11. Nitrate Absent 
12. Oxalate Absent 
13. Fluoride Absent 
14. Borate Absent 
15. Lead Absent 
16. Aluminium Absent 
17. Zinc Absent 
18. Calcium Absent 
19. Magnesium Absent 
20. Ammonium Absent 
21. Potassium Absent 
22. Mercury Absent 
23. Arsenic Absent 
24. Starch Absent 
25. Reducing sugar Absent 
26. Tannic Acid Absent 
27. Unsaturated compound Absent 
28. Amino Acid Absent 
29. Type of compounds Absent 
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DISCUSSION 
The main aim of the treatment was to study the Therapeutic effect of the drug 
Amirtharasa Mathirai to reduce pain and restricted joint movements in the disease Uthira 
Vatha Suronitham. The clinical features of Uthiravatha Suronitham can be correlated to 
Rheumatoid Arthritis in modern science. Rheumatoid Arthritis is a chronic inflammatory,   
destructive, and deforming symmetrical poly arthritis associated with symmetrical 
involvement of joints. 
            Uthiravatha Suronitham is a Vatha disease in which, there occur a derangement of 
Vatha thathu and Pitha thathu.  
            Vatha thathu is responsible for the functioning of the Udal thathukal uniformly. 
Hence derangement of the Vatha kutram leads to impairment in Udal thathukal and in turn 
produces symptoms like pricking pain, body ache, difficulty in flexion and extension of 
joints, mental distress etc. 
 The drugs which possess anti-vatha property as mentioned in Siddha literature were 
selected and the trial drugs were prepared by the Author in the Gunapadam practical 
laboratory of  National Institute of Siddha, after getting proper authentication of raw drugs 
from the Medicinal botany department at NIS, Chennai 47, and Chemistry department in 
Siddha central Research Institute  Arumbakkam Chennai 106, under the supervision of the 
members of the teaching faculty and guided by the Head of the Department of Sirappu 
Maruthuvam of the National Institute of Siddha, Chennai - 47. The trial drug was prepared by 
the standard operating procedure as mentioned in the protocol. 
The safety of the trial drug usage and standardization of the trial drug through 
biochemical analysis were also ensured during the study. 
 The Preclinical toxicity studies (Acute toxicity) for the above said trial drug was 
conducted at National Institute of Siddha after getting the proper acceptance and permission 
from the Institutional Animal Ethical Committee. The trial drug was proved to be safe for 
human beings from the observations made from the study. 
The Biochemical qualitative and quantitative analysis were done at the biochemistry 
lab of NIS and IIT Chennai respectively. It revealed the presence of effective minerals and 
the existence of the drug molecules at micro level. 
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              The clinical study was conducted with a well defined protocol and a proper proforma 
after the approval of the Institutional Ethical Committee. After screening  patients  reporting 
at the OPD of department of Sirappu Maruthuvam, 40 cases were selected for induction to the 
trial. Before enrollment into the trial the informed consent was obtained from the patients. 
 40 patients of  both genders were recruited for this study. Among the 40 patients 20 
were OPD patients and the remaining 20 were IPD patients. Among the 20 IPD patients 10 
Patients received varmam treatment along with the trial drugs. For In-Patients, who were not 
in a situation to stay in the hospital for a long time, were advised to attend the Out-Patient 
Department of Sirappu Maruthuvam for further follow- up.   
            The treatment was aimed at normalizing the deranged thodams and providing relief 
from symptoms. Before treatment the patients were advised to take Agasthiyar kuzhambu- 
130 mg  with ginger juice in early morning for purgation. The patient was advised to take rest 
without internal medicine. 
The patients were treated with trial drugs Amirtharasa Mathirai twice a day with 
water  and  Suronitha Vatha Ennai (external) for 48 days . Patients were instructed to take the 
medicines regularly  advised to follow pathiyam  (avoid tamarind, tubers, etc) and advised to 
avoid cold exposure . Out-Patients were asked to visit the hospital once in 7 days. For Out-
Patients the drugs were given for 48 days and the clinical assessment was done on 0th day, 8th 
day, 15th day, 22th day , 29th day, 36th day, 43th day and 49th day.  
  After the treatment, the patients were advised to visit the Out-Patient ward of 
Department of Sirappu Maruthuvam for another 2 months for follow-up. The results observed 
during the study period were discussed by the author below.   
Among the 40 patients selected,  
    According to the Gender the disease was found to be higher in females (82.5%) and 
lower in males (17.5%). 
    In Age group  15% of the affected patients came under the age group between 20-
30 years. 27.5 % of the patients fall under the age group between 31-40 years, 37.5 % of them 
are between 41-50 years and 20 % of them is between 51-60 years. 
    In my study while seeing  socio-economic status  of the patients the disease was 
found to be higher in the  Low income group 52.5%.  lower in the Middle income group 
35%.moderate in the high income group12.5%. 
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In Occupational  distribution,31 cases (77.5%) were house wifes, 2 cases(5% ) were 
social worker,1 Cases( 2.5%) 1 were Tailor, 5 Cases (12.5%)were coolie, 1 Cases (2.5%) 
were Lab asst. 
 In diet  Non vegetarian (80%) is very higher than the vegetarian (20%). 
In Thinai  80% of cases were from Neithal and 20% of cases were from marutham 
illam. As per Siddha literatures; it is mentioned that vaatha diseases are common in Neithal 
nilam. This study also reveals the majority cases of this disease in Neithal thinai. 
 In  Paruva Kaalam (Season) Out of 40 cases 55% cases were taken in Muthuvenil 
kaalam and 45% cases were taken in Kaarkaalam. 
 In Gunam 70% of cases had Thamo gunam, 27.5% of cases had Raso gunam, 2.5% 
of cases had Sathuva gunam. 
 In Body constitution Out of 40 cases, 100 % were came under Thontha thegi. 
While seeing  the Naadi, Vatha pitha naadi was found in 8 cases (20%), Pitha vatha 
naadi was found in 24 cases (60%), Pitha kaba naadi was found in 6 cases (15%), Kaba pitha 
naadi was found in 2 cases (5%). 
In vatham, viyaanan and samanan was affected in all cases (100%), 15 cases  
(37.5%) affected in Abanan, and 2 cases (5%)affected in Devathathan. 
            Among 40 cases, Saathagam was affected in all 40 cases (100%) , Ranjagam and 
Prasagam were affected in 20 cases(50%), Analam was affected in 6 cases (15%) . 
            In Iyam Only santhigam was affected in all the 40 cases. 
In Envagai Thervu , Naa and sparisam were affected in 50% of patients whereas 
Vizhi was affected in 62.5%  and Malam was affected in 37.5% of patients.  
In Neikkuri , Vatha neer was found in 2 cases(5%) , Pitha neer was found in  9  cases 
(22.5%) and Kaba neer was  found in 29 cases (72.5%). 
 In Udal thaathukkal  Saram, Oon, Kozhuppu and Enbu were affected in all 40 cases 
and  Senneer was affected in 5 cases only.  
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           In Kanmendrium Kai and Kaal were affected in 100% cases, Eruvai was affected in 
37.5%  cases. 
            In Duration of illness,  about 35% cases had 3-10 yrs of duration, 17.5% cases had  
2-3 yrs of duration, 20% cases had 1-2 yrs of duration,  17.5% cases had  6 mon – 1yr of 
duration and  10% cases had 6 months of duration. 
            According to the mode of onset  12.5% of cases had acute onset of illness, 30% of 
cases had subacute and  57.5% of cases had chronic onset of illness.  
According to the clinical features  all 100% of cases had pain, swelling, early 
morning stiffness, warmth, tenderness, and restricted movements .10% cases had fever, 
12.5% cases had anorexia, 17.5% cases had deformities, 57.5% cases had polyarthralgia 
symptoms 
Among the Deformities, 17.5% of cases had spindle shaped deformity, 10% of cases 
had hallus valgus derormity, 5% of cases had ulnar deviation and  2.5% of cases had swan 
neck  deformity. 
 In my study, wrist and MCP joints were involved in 92.5% cases,  Knee and PIP 
joints were  involved  in 90% , Ankle joint was involved in 87.5% cases,  Elbow joint was 
involved in 85% cases , Lumbosacral joint was  involved in 62.5% cases,  Cervical vertebrae 
were involved in 37.5% cases, and  Hip joint was involved in 25% cases. 
 After treatment Out of 40 cases  
             In my study, Before treatment 67.5% of cases had Severe pain, 27.5% of cases had 
Moderate pain and 5% of cases  had Mild pain. 
 After treatment 7.5% of cases had Severe pain, 10% of cases had Moderate pain,  
60% of cases  had Mild pain and 22.5%of cases had No pain. 
According to the Restriction, After the treatment among 40 cases, Restriction was 
reduced in 70% of cases,  Mild restriction was found in 22.5% of cases, Moderate restriction 
was found in 7.5% of cases. 
Overall Results are 70% cases showed Good improvement,15% cases showed  
Moderate  improvement, 7.5%  cases showed  Mild  improvement. 
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Laboratory investigation of  blood and urine were done for all 40 cases. There were 
no significant changes in blood and urine parameters before and after treatment. 
Patients treated with Varmam showed very good results since there was marked 
reduction in the Pain of  Uthiravatha Suronitham patients in this clinical trial. 
             The pain assessment was done in all the 40 patients participated in the trial  The 
mean pain score before treatment is 6.78  after treatment it is reduced to 2.33.  Hence this 
study reveals Varmam treatment along with trial medicines is to be very effective in the 
treatment of Uthiravatha Suronitham. 
 Varmam treatment along with their internal medicine, 
The mean pain score of the 10 patients who received varmam treatment before 
treatment is  6.6  and after treatment it is reduced to  1.7  
The acute toxicity study was conducted for the trial drug Uthiravatha Suronitham in 
National Institute of Siddha and it showed no abnormal results. Hence the safety of the trial 
drug was also proved. 
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SUMMARY 
 
      Uthiravatha Suronitham, a type of vatha disease described by Yugi Muni is 
clinically identical with Rheumatoid Arthritis..It is the most common persistent inflammatory 
arthritis, occurring throughout the world and in all ethnic groups. The clinical course is 
prolonged, with intermittent exacerbations and remissions. 
     The aim of the study was to evaluate the efficacy of Amirtharasa mathirai and 
Suronithavatha ennai in Uthiravatha Suronitham. 
     The study was accepted by Institutional screening committee and then approved by 
the Institutional Ethical Committee (IEC) and the Institutional Animal Ethical Committee 
(IAEC). 
      For my study, the 40 cases of Uthiravatha suronitham were diagnosed clinically, 
based on the inclusion and exclusion criteria in the approved protocol. Out of the 40 cases, 20 
cases  were admitted and treated with the trial drugs in the In-patient ward and the rest were 
treated in outpatient department of Sirappu Maruthuvam in Ayothidoss Pandithar Hospital 
attached to National Institute of Siddha,Tambaram Sanitorium, Chennai - 47. 
                  Among the 20 Ip patients, 10 IP patients were treated by Varmam treatment along 
with the trial medicine and remaining 30 cases were treated only with the trial drugs for 48 
days. 
      In this study , first the patients were well informed about the study and they were 
asked to sign the consent form. After signing the consent form, information sheet and diatery 
advice forms were given to the patients. 
     The various Siddha methods of examination of the disease were carried out and the 
data were recorded in the prescribed Proforma for the 40 selected cases. 
     A day before starting the treatment purgation was given by administering 
Agasthiyar Kuzhambu– 1 kundri (130 mgs) early morning with Ginger juice to bring the 
Thirithodam to equilibrium. 
    From the second day onwards Amirtharasa mathirai - one tablet (130 mgs) twice a 
day along with water was given internally and Suronitha vatha ennai for external use were 
given to the patients for 48 days. 
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    During the period of treatment all the patients were put under Pathiyam (specific 
dietary regimen for the disease). 
    The prognosis of the patients during each visit was entered and monitored for any 
adverse drug reactions or poor patient compliance, investigation reports were recorded before 
and after treatment. 
    Observation made during the clinical study showed that the trial drug was clinically 
effective. Out of the 40 cases 28 cases showed good improvement, 6 cases had moderate 
improvement, 3 cases showed only mild improvement and 3 cases had no improvement. 
             Acute toxicity study reveals that Amirtharasa mathirai at the dose 4.68mg/animal did 
not exhibit any mortality in mice. In Necropsy, the organs of the animal such as, Liver, Heart, 
Lungs, Pancreas, Spleen, Stomach, Intestine, Kidney, Urinary bladder, Uterus all appeared 
normal. 
   Therefore it is assumed that the drug is safe for humans. 
    Bio-chemical analysis revealed that the drug contains Silicate, Carbonate, Sulphide, 
Chloride, Iron, Alkaloids. 
     The qualitative and quantitative study on the trial drug conducted at Sophisticated 
Analytical Instrument Facility (SAIF), IIT, Chennai-36 revealed that the trial drug does not 
possess any heavy metals like lead, cadmium etc., 
     The pain assessment was done in all the 40 patients participated in the trial using 
the universal pain assessment scale and at the end of the study the results showed, the mean 
pain score before treatment was 6.78  and after treatment it was reduced to  2.33 
     Among the 20 IP patients, 10 IP patients were given Varmam treatment along with 
their internal medicine. The remaining 10 IP patients didn’t received varmam treatment. The 
results are compared at the end of the study. The mean pain score of the 10 patients who 
received varmam treatment before treatment is  6.6  and after treatment it is reduced to  1.7 
Hence varmam treatment along with internal medicine is more effective in the treatment of 
rheumatoid arthritis 
      From this clinical trial it could be inferred that Amirtharasa mathirai and 
Suronitha vatha ennai possess good therapeutic efficacy in Uthiravatha suronitham. 
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 The outcome of the trial medicines were assessed by grading method and the results 
were as follows: 
Good improvement  -  28 patients ( 70%) 
 Moderate improvement     -  6 patients ( 15%) 
Mild improvement  -  3 patients (7.5 %) 
No improvement  -  3 patients (7.5 %) 
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CONCLUSION 
 
Acute toxicity study reveals that the trial drug Amirtharasa mathirai is safe. The 
results of the clinical trial indicate that the trial drugs are clinically effective in Uthiravatha 
suronitham patients. No adverse effects were reported during the course of treatment and 
there were no significant variations seen in hepatic and renal studies before and after the 
treatment.  
Hence the trial drugs are considered as safe. 
The qualitative and quantitative study on the trial drug revealed that the drug does not 
contain any heavy metals like lead, cadmium etc. The particle size of the trial drug is 0.25 – 
0.5 micron that makes the drug absorption better. 
The study shows that about 82.5% of reported patients were women and after 
treatment most of the patients were comfortable and returned to their daily activity 
independent of others. Hence if the pain gets reduced in those individuals helping them to do 
their own daily routine by themselves is itself a big relief for those people.  
Hence the study concludes that, the trial drugs are clinically effective in reducing the 
pain, swelling and restricted movement in Uthiravatha suronitham patients. However further 
work with large number of patients should be carried out towards finding the ideal dose 
response. 
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NATIONAL INSTITUTE OF SIDDHA 
ACUTE TOXICITY STUDY OF AMIRTHARASA MATHIRAI 
[WHO guidelines, 1993] 
Principle: 
    Acute toxicity was carried out in Swiss albino mice with a single exposure of 
10 times of the recommended therapeutic dose of test compound the study duration will be 14 
days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 10 
Acclimatization Period : 7 Days 
Clinical dose   : 260 mg\day 
S.No Group No of mice 
1 Vehicle control (saline) 10  (5 male, 5 female) 
 
2 
Toxic dose 
10X therapeutic dose 
(4.68mg) 
10  (5 male, 5 female) 
 
Test Animals  
       Test animals were obtained from the animal laboratory of the King institute, 
Chennai and stocked at National institute of siddha, Chennai. All the animals were kept under 
standard environmental condition (27+ or – 2 degree c).The animals had free access to water 
and standard pellet diet (Sai Durga foods pvt.ltd, Bangalore).The principles of laboratory 
animal care were followed and the  Institutional ethical committee approved the use of 
animals and the study design. (1248/ac/09/CPCSEA/February/ 2012) 
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 Route of administration: 
  Oral route was selected, because it is the normal route of clinical 
administration. 
Test substance and vehicle 
        The Amirtharasa mathirai is Black in colour.  The test substance is insoluble in 
water, in order to obtain and ensure the uniformity in drug distribution the drug is dissolved 
by aqueous Tween 80 solution (10%).  
Administration of doses 
            Amirtharasa mathirai was suspended in aqueous Tween 80 solution (10%), 
with uniform mixing and it was administered to the groups in a single oral dose .The control 
groups were received equal volume of the vehicle. The animals were weighed before giving 
the drug. The dose level was calculated according to body weight, and surface area. Since the 
clinical dose was 260mg\day it was converted to animal dose (4.68mg) and then 
administered. The principle of laboratory animal care was followed. 
Observations 
  Observations were made and recorded systematically and continuously 
observed as per the guideline after substance administration. The animals were monitored for 
behavioural parameters like 
1. Awareness 
- Alertness 
- Visual placing 
- Stereotype 
- Passivity 
2. Mood 
-  Grooming 
-  Restlessness 
-  Irritability 
-  Fearfulness 
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3. Motor activity 
- Spontaneous activity 
- Reactivity 
- Touch response 
- Pain response.  
Animals were observed for body weight and mortality for 14 days. If animals died 
during the period of study, the animals were sacrificed.  At the end of the 14th day all animals 
were sacrificed and necropsy was done. 
Body Weight 
  Individual weight of animals was determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the end 
of the test, surving animals were weighed and sacrificed. 
Results:   
Amirtharasa mathirai at the dose 4.68mg/animal did not exhibit any mortality in mice. 
  No behavior changes were noted for the first 4 hours and for the next 24 hours 
and throughout the study period of 14 days. No weight reduction was noted before and after 
the acute study duration. Reflexes were found to be normal before and after the study. All 
other observations were found to be normal before and after the study. In Necropsy, the 
organs of the animal such as, Liver, Heart, Lungs, Pancreas, Spleen, Stomach, Intestine, 
Kidney, Urinary bladder, Uterus all appeared normal. 
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SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
HR SEM-METHODOLOGY 
An SEM is essentially a high magnification microscope, which uses a focussed 
scanned electron beam to produce images of the sample, both top-down and, with the 
necessary sample preparation, cross-sections. The primary electron beam interacts with the 
sample in a number of key ways:- 
· Primary electrons generate low energy secondary electrons, which tend to 
emphasize the topographic nature of the specimen.  
· Primary electrons can be backscattered which produces images with a high degree 
of atomic number (Z) contrast.  
· Ionized atoms can relax by electron shell-to-shell transitions, which lead to either 
X-ray emission or Auger electron ejection. The X-rays emitted are characteristic 
of the elements in the top few μm of the sample.  
SAMPLE PREPARATION: 
Sample preparation can be minimal or elaborate for SEM analysis, depending on the 
nature of the samples and the data required. Minimal preparation includes acquisition of a 
sample that will fit into the SEM chamber and some accommodation to prevent charge build-
up on electrically insulating samples. Most electrically insulating samples are coated with a 
thin layer of conducting material, commonly carbon, gold, or some other metal or alloy. The 
choice of material for conductive coatings depends on the data to be acquired: carbon is most 
desirable if elemental analysis is a priority, while metal coatings are most effective for high 
resolution electron imaging applications. Alternatively, an electrically insulating sample can 
be examined without a conductive coating in an instrument capable of "low vacuum" 
operation.  
 The SEM is carried out by using FEI-Quanta FEG 200-High Resolution Instrument. 
 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12x to greater than 1, 00,000 X 
Application : To evaluate grain size, particle size distributions, material homogeneity   
   and  inter metallic distributions. 
Experimental Procedure: Done at SAIF, IIT Madras, Chennai-36. 
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Sample preparation: 
                Sample preparation can be minimal or elaborate for SEM analysis, depending on 
the nature of the samples and the data required. Minimal preparation includes acquisition of a 
sample that will fit into the SEM chamber and some accommodation to prevent charge build-
up on electrically insulating samples. Most electrically insulating samples are coated with a 
thin layer of conducting material, commonly carbon, gold, or some other metal or alloy. The 
choice of material for conductive coatings depends on the data to be acquired: carbon is most 
desirable if elemental analysis is a priority, while metal coatings are most effective for high 
resolution electron imaging applications. Alternatively, an electrically insulating sample can 
be examined without a conductive coating in an instrument capable of "low vacuum" 
operation.  
                                                                     Table-1 
Colour characters of  Amirtharasa Mathirai 
S No Solvent used Under ordinary light Under ultra violet light 
1 PPM Black Black 
PPM-Powdered plant material 
Table-2 
Physicochemical properties of Gandhaga parpam 
S. No. Parameters Values obtained (%w/w) Heavy/ toxic metals 
1 Total ash value 9.73 Lead BDL 
2 Acid insoluble ash 0.95 Cadmium BDL 
3 Water soluble ash 5.9 Mercury 4.356mg/L 
4 Moisture content 8.82 Arsenic BDL 
5 Foreign organic matter 7.98 Volatile oil BDL 
 
BDL-Below detection limit 
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Table-3 
Colour, nature and percent yields of extracts of Gandhaga parpam 
 
S.No. Extract 
Solvents 
Colour Nature % 
Yield(w/w) 
 
SEM 
Particle size 
in micron 
pH 
1. Water Black Solid 45 0.25 - 0.5 7.7-7.8 
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SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION SPECTROMETRY 
Introduction  
Inductively coupled plasma optical emission spectrometry (ICP-OES), is an analytical 
technique used for the detection of trace metals. It is a type of emission spectroscopy that 
uses the inductively coupled plasma to produce excited atoms and ions that emit 
electromagnetic radiation at wavelengths characteristic of a particular element. The intensity 
of this emission is indicative of the concentration of the element within the sample. 
Principle 
A Perkin-Elmer Optima ICP spectrometer is used for routine ICP-OES analysis. First, 
a high-energy radio frequency field is impinged upon a stream of argon gas. Then, a spark is 
used to ionize the argon gas, which forms a sustained plasma due to inductive coupling with 
the high energy radio frequency field and the continuous supply of fresh argon to the plasma 
torch. This plasma has solutions passed into it in the form of a fine aerosol. The aerosol is 
dried, the dried particles broken apart, and the individual elements are excited by interaction 
with the excited state argon in the plasma. As each atom returns to its ground state from the 
excited state, they emit light at wavelengths characteristic of the elements from which they 
originate. The emission intensity for each element is monitored for each standard solution and 
a calibration curve of emission intensity versus element concentration can be constructed. 
Extraction of information 
Obtaining qualitative information, i.e., what elements are present in the sample, 
involves identifying the presence of emission at the wavelengths characteristic of the 
elements of interest.  Obtaining quantitative information, i.e., how much of an element is in 
the sample, can be accomplished using plots of emission intensity versus concentration called 
calibration curves. Typical calibration graph is illustrated below 
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Typical ICP Calibration curve 
Experimental Procedure: Done at SAIF, IIT Madras, Chennai-36 
Perkin Elmer Oplima 5300DV  
40 M Hz RF generator; 
Range: 165-782 nm;  
Detection limit: Upto ppb level using SCD detector 
 Sample preparation – Microwave Digestion   
· Weigh 0.25g of test sample and transfer into a liner provided with the instrument. 
· Slowly add 9ml of Nitric acid or Sulphuric acid such that no piece of sample sticks on 
the slides. 
· Mix thoroughly and allow reacting for few minutes. 
· Place the liner in the vessel jacket. 
· Close the screw cap hand-tight in clockwise direction. 
· Seal the vessel and place in the rotor fixed in microwave. 
· Set temperature to 180°C for 5 minutes; hold at 180°C for least 10 minutes. 
· Allow the vessels to cool down to a vessel interior temperature below 60°C and to a 
vessel surface temperature (IR) below 50°C before removing the rotor. 
· The digested sample was made upto 100ml with millipore water. 
· If visible insoluble particles exist, solution could be filtered through whatmann filter 
paper. 
· Transfer the digested solution into plastic containers and label them properly. 
 
127 
 
Advantages: 
Good general-purpose technique 
Good dynamic range 
Accommodates organic solvents 
Multi-elemental technique 
Disadvantages 
Cost of the instrument 
Limits of detection 
Sample volume requirements 
Spectral interferences for unknown/complicated matrices 
Sample description: Amirtharasa Mathirai 
Instrument            :  PERKIN ELMER OPTIMA 5300DV ICP-OES 
 Analyte Mean 
As 193.696 BDL 
Ca 317.933 5.21 mg/L 
Cd 226.502 BDL 
Hg 253.652 BDL  
Fe 238.204 1.254 mg/L 
K 766.490 4.266 mg/L 
Na 589.592 9.548 mg/L 
P 213.617 5.692 mg/L 
Pb 230.204 BDL 
S 181.975 17.154 mg/L 
References: 
· OPTIMA 5000 SERIES Hardware Guide. 
· Concepts, Instrumentation and Techniques in Inductively Coupled Plasma Optical 
Emission Spectrometry by Charles B. Boss and Kenneth J. Fredeen 
· Handbook of Inductively Coupled Plasma Spectrometry By Michael Thompson and J. 
Nicholas Walsh.                                                                                               
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE-CLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM l - SCREENING & SELECTION PROFORMA 
1. SL.NO: -----------------                                      OP /IP NO: -------------                               
2. NAME: -------------------------------------     3. AGE/GENDER: -------      
4. RELIGION : -----------------                               5. OCCUPATION: -----------------  
6. INCOME: ---------------                 
 7. ADDRESS AND CONTACT NUM: -------------------------  
8. INCLUSION CRITERIA 
· Age: 20- 60  years       
· Sex: Both male and female 
· Symmetrical joint involvement 
· Arthritis of three or more joints 
· Rheumatoid factor positive or negative 
· Morning stiffness. 
· Deformities like Swan neck deformity and Button hole deformity 
· Swelling especially in the inter-phalangeal joint. 
· Patients willing for admission and stay in IPD or willing to attend OPD 
· Patient willing to undergo Radiological investigation and 
laboratory investigation.                                                        
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· Patient willing to sign the informed consent stating that he/she will 
consciously stick to the treatment during 48 days but can opt out of the trial of 
his/her own conscious discretion.  
The patients with complaints of any three of the clinical signs and symptoms said 
above may be included in this study  
9. EXCLUSION CRITERIA: 
· Drug addicts 
· Pregnancy and lactation 
· Tubercular arthritis 
· Any other serious systemic illness 
· Osteoarthritis 
· Psoriatic arthritis 
· Gouty arthritis 
· Sexually transmitted diseases 
ADMITTED TO TRAIL:    YES                   NO 
                         
       OPD    IPD 
If Yes : 
 
 
 
Date:        
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD 
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                               NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE-CLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
                                    
 
                                  FORM lI -HISTORY PROFORMA 
 
 
1.  SI NO:------         2 OP /IP NO: -------------      3. NAME :-----------------------          
4.  AGE/GENDER: -------                  5.  OCCUPATION: -----------------------         
6. MARITAL STATUS :   Married/Unmarried        
7. COMPLAINTS & DURATION:   
 
 
                                                                                                                                                                                     
 
 
 
8. PERSONAL HISTORY: 
 
PERSONAL HABITS YES NO IF YES, SPECIFY DURATION/QTY 
           Smoking    
          Tobacco Chewing    
           Alcohol    
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9. HISTORY OF PREVIOUS ILLNESS: 
 
 
 
10. FAMILY HISTORY 
 Whether this problem runs in family             1. Yes                               2. No            
 If yes, mention the relationship of affected person(s) 
                         1._________________            2._________________ 
11. DIETARY HABITS     
                          1. Vegetarian                                            2. Non-Vegetarian     
 
12. MENSTRUAL AND OBSTETRIC HISTORY: 
 
 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD                       
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   NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST - GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE-CLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM III - CLINICAL ASSESSMENT PROFORMA 
 
1. SI NO:------         2 OP /IP NO: -------------      3. NAME :----------------------          
4. DATE OF ASSESSMENT   :    ---------------------- 
GENERAL EXAMINATION: 
Height (cms)                : ………………………….                   
Weight (Kg)    : ………………………….                   
Temperature (°F)     : ………………………….                   
Pulse rate (per min)   : ………………………….                   
Heart rate (/min)   : ………………………….                   
Respiratory rate (/min)  : ………………………….                   
Blood pressure (mm/Hg)       : ………………………….           
                                                     Present           Absent 
Pallor  
Jaundice 
Cyanosis 
Lymphadenopathy 
Pedal edema 
Clubbing 
Jugular vein pulsation 
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EXAMINATION OF OTHER SYSTEMS: 
Cardiovascular System  : ………………………….                   
Respiratory System   : ………………………….                   
Gastro-intestinal system  : ………………………….                   
Central Nervous System  : ………………………….                   
Urogenital System   : ………………………….                   
Endocrine System   : ………………………….                   
SIDDHA SYSTEM OF EXAMINATION 
1. ENVAGAI THERVU:  
 1. NAADI: [PULSE PERCEPTION] 
2. NAA:[TONGUE] 
Naa 
Before Treatment After Treatment 
 
  
3. NIRAM: [COMPLEXION]   
     1. Vatham         
     2. Pitham 
     3. Kabam  
4. MOZHI: [VOICE] 
      1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
 
Nadi Nadai 
0th  
Day 
8th  
Day 
15th 
Day 
22th 
Day 
29th 
Day 
36th 
Day 
43rd 
Day 
49th 
Day 
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5. VIZHI: [EYES]  
6. MALAM; [BOWEL HABITS / STOOLS] 
 
                Malam Before Treatment After Treatment 
 
 
 
7. URINE EXAMINATION   
 
NEIKKURI Before Treatment After Treatment 
Snake like pattern   
Annular/Ringed pattern   
Pearl beaded pattern   
Other pattern   
        8. SPARISAM:  
 
                Sparisam Before Treatment After Treatment 
 
Warmth/cold/normal 
 
 
Warmth/cold/normal 
 
   
0th  
Day 
8th  
Day 
15th  
Day 
22nd  
Day 
29th  
Day 
36th  
Day 
43rd  
Day 
49th  
Day 
        
NEERKKURI Before Treatment After Treatment 
    Niram 
 
  
    Edai 
 
  
    Manam 
 
  
    Nurai   
    Enjal   
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           9. THEGI: [TYPE OF BODY CONSTITUTION]    
       Vatha Thegi  
       Pitham Thegi  
       Kabam Thegi  
       Thondha Thegi  
10. NILAM: [LAND WHERE PATIENT LIVED MOST] 
  Kurinji                  Mullai                  Marutham                   Neithal                  Palai 
11. KAALAM 
Kaarkalam   (Aavani-Puratasi)                              Pinpanikalam (Maasi-Panguni)     
Koothirkalam (Iipasi-Karthigai)                            Ilavenil (Chithirai-Vaigasi) 
Munpanikalam (Marghazi-Thai)                           Muthuvenil (Aani-Aadi) 
      12. GUNAM 
Sathuvam                        Rasatham                       Thamasam 
13. AIMPORIGAL (SENSORY ORGANS) 
 
  
 Before Treatment After Treatment 
Mei 
 
Normal/Affected Normal/Affected 
Vai 
 
Normal/Affected Normal/Affected 
Kan 
 
Normal/Affected Normal/Affected 
Mookku Normal/Affected Normal/Affected 
Sevi Normal/Affected Normal/Affected 
136 
 
14. KANMENDRIYANGAL (MOTOR ORGANS) 
    15. KOSANGAL (SHEATH)   
 Before Treatment After Treatment 
Annamaya Kosam Normal/Affected Normal/Affected 
Pranamaya Kosam Normal/Affected Normal/Affected 
Manomaya Kosam Normal/Affected Normal/Affected 
Vignanamaya Kosam Normal/Affected Normal/Affected 
Ananthamaya Kosam Normal/Affected Normal/Affected 
16.MUKKUTRAM: [UYIR THATHUKKAL] 
A.VALI: 
 Before Treatment After Treatment 
Kai  Normal/Affected Normal/Affected 
Kaal  Normal/Affected Normal/Affected 
Vaai    Normal/Affected Normal/Affected 
Eruvai  Normal/Affected Normal/Affected 
Karuvai   Normal/Affected Normal/Affected 
 Before Treatment After Treatment 
Praanan Normal/Affected Normal/Affected 
Abaanan Normal/Affected Normal/Affected 
Samaanan Normal/Affected Normal/Affected 
Udhaanan Normal/Affected Normal/Affected 
Viyaanan Normal/Affected Normal/Affected 
Naagan Normal/Affected Normal/Affected 
Koorman Normal/Affected Normal/Affected 
Kirukaran Normal/Affected Normal/Affected 
Devathathan Normal/Affected Normal/Affected 
Dhananjeyan Normal/Affected Normal/Affected 
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B) AZHAL:   
 Before Treatment After Treatment 
Analapitham Normal/Affected Normal/Affected 
Prasakam Normal/Affected Normal/Affected 
Ranjakam Normal/Affected Normal/Affected 
Aalosakam Normal/Affected Normal/Affected 
Saathakam Normal/Affected Normal/Affected 
C) IYAM: 
 Before Treatment After Treatment 
Avalambagam Normal/Affected Normal/Affected 
Kilethagam Normal/Affected Normal/Affected 
Pothagam Normal/Affected Normal/Affected 
Tharpagam Normal/Affected Normal/Affected 
Santhigam Normal/Affected Normal/Affected 
 17.SEVEN UDAL DHATHUS: (SEVEN SOMATIC COMPONENTS)  
 Before Treatment After Treatment 
Saaram Normal/Affected Normal/Affected 
Senneer Normal/Affected Normal/Affected 
Oon Normal/Affected Normal/Affected 
Kozhuppu Normal/Affected Normal/Affected 
Enbu Normal/Affected Normal/Affected 
Moolai 
 
Normal/Affected Normal/Affected 
Sukkilam/ 
Suronitham  Normal/Affected Normal/Affected 
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18.CLINICAL EXAMINATION AND ASSESSMENT OF JOINTS: 
INSPECTION 
PALPATION: 
 
Sl. 
No  
0th  
Day 
8th  
Day 
15th  
Day 
22nd  
Day 
29th  
Day 
36th  
Day 
43rd  
Day 
49th  
Day 
1 Muscle spasm 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
2 
Local 
lymph 
adenopat
hy 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
3 
Major 
Joint 
Swelling 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
4 
Minor 
Joint 
Swelling 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
5 Nodules Present/ Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
6 
Skin over 
the joint 
 
Nor/ 
Reddis 
Nor/ 
Reddis 
Nor/ 
Reddis 
Nor/ 
Reddis 
Nor/ 
Reddis 
Nor/ 
Reddis 
Nor/ 
Reddis 
Nor/ 
Reddis 
Sl. 
No  
0th  
Day 
8th  
Day 
15th  
Day 
22nd  
Day 
29th  
Day 
36th  
Day 
43rd  
Day 
49th  
Day 
1 Tenderness Present/ Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
2 Local heat Present/ Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
3 
Local 
lymph 
adenopathy 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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MOVEMENTS 
 
DEFORMITIES: 
 0
th  
Day 
8th  
Day 
15th  
Day 
22nd  
Day 
29th  
Day 
36th  
Day 
43rd 
Day 
49th 
Day 
Swan neck 
deformity 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/ 
 Absent 
Button hole 
deformity 
Present/ 
Absent 
Present/
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/
Absent 
Present/
Absent 
Z shaped 
deformity 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Ulnar 
deviation of 
hand 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Ulnar 
deviation of 
foot 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent Present/ Absent 
Hallus valgus Present/ Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Spindled 
appearance of 
fingers 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 0
th  
Day 
8th  
Day 
15th  
Day 
22nd  
Day 
29th  
Day 
36th 
Day 
43rd 
Day 
49th 
Day 
PAIN 
 Onset: 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
Sudden/ 
Gradual 
 Nature 
of pain 
Mild/ 
Moderate
/ Severe 
Mild/ 
Moderate
/ Severe 
Mild/ 
Moderate/ 
Severe 
Mild/ 
Moderate
/ Severe 
Mild/ 
Moderate
/ Severe 
Mild/ 
Moderate
/ Severe 
Mild/ 
Moderate
/Severe 
Mild/ 
Moderate/ 
Severe 
 Early 
morn  
Stiff 
ness 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Restric 
tion of 
move 
ments 
 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
Fully/ 
Partial/ 
No 
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19.CLINICAL SYMPTOMS 
CLINICAL  
SYMPTOMS 
0th  
Day 
8th  
Day 
15th  
Day 
22nd  
Day 
29th  
Day 
36th 
Day 
43rd 
Day 
49th 
Day 
Arthritis of more 
than 3 joints      
   
Swelling of 
joints 
(especially in 
interphalangeal 
joints) 
     
   
Morning 
stiffness > 1 Hr      
   
Symmetrical 
arthritis      
   
Mental 
depression      
   
Anorexia         
Low grade fever         
Serum 
Rheumatoid 
factor 
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UNIVERSAL PAIN ASSESSMENT SCALE 
 
 Grade   0    :  No Pain 
                Grade 1 -3 :   Mild pain 
                 Grade 4-6 :   Moderate pain 
                       Grade 7-10 :   Severe pain     
 
GRADATION: 
· G 1 – Able to perform normal duties 
· G II – Moderate Restriction – Self care is possible 
· G III – Marked restriction – Limited self care/ Some assistance required. 
· G IV – Confined to bed or wheel chair 
 
(Reference: Clinical Manual for Nursing Practise.(National Institute of Health Warren 
Grant Magnuson Clinical Center) 
 
 
Date : 
      
Station: 
 
Signature of the Investigator: 
 
 
 
Signature of the Lecturer:                                                        Signature of the HOD 
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     NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE-CLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
VARMAM THERAPY ASSESSMENT FORM 
OBSERVATION CHART 
SERIAL NO:       OP/IP NO: 
NAME:      AGE/ GENDER:                                  
COMPLAINTS AND DURATION: 
 
 
 
 
VARMAM POINTS (IP PATIENTS):    
1. Mudichu  5. Komberi  
2. Kavuli   6. Viruthi 
3. Chavvu   7. Ullangal vellai 
4. Mozhi piralgai   8. Ullangai vellai 
Sl.
no Date Pain Tenderness 
Radiating 
pain Stiffness Numbness 
Duration 
of relief 
Other 
clinical 
features. 
1         
2         
3         
4         
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Sl.
no Date Pain Tenderness 
Radiating 
pain 
Stiffness Numbness 
Duration 
of relief 
Other 
clinical 
features. 
5         
6         
7         
8         
9         
10         
11         
12         
13         
14         
15         
16         
17         
18         
19         
20         
21         
22         
23         
24         
25         
26         
27         
28         
29         
30         
31         
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OTHER REMARKS: 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD 
Sl.
no Date Pain Tenderness 
Radiating 
pain 
Stiffness Numbness 
Duration 
of relief 
Other 
clinical 
features. 
32         
33         
34         
35         
36         
37         
38         
39         
40         
41         
42         
43         
44         
45         
46         
47         
48         
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST -GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE-CLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM lV - LABORATORY INVESTIGATIONS 
   1. SI NO:------                                  2. OP /IP NO: -------------       
   3. NAME :-----------------------         4. AGE/GENDER :-------            
             
 BLOOD INVESTIGATION NORMAL VALUES 
BEFORE TMT 
(with date) 
AFTER TMT 
(with date) 
Hb( gm/dL) M:13-18 W:11.-16   
T.RBC(milli/cu.mm) M:4.5-6.5 W:3.5-5.5   
ESR (mm) 
½ hr. -   
1 hr. 
M: 0-10 
         W: 0-20 
  
T.WBC (/cu.mm) 4000-11000   
 
Differential 
Count (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Esonophils 1-6   
Basophils 0-1   
Platelets (lak/ cubic mm) 1,50000-500000   
Blood 
glucose 
(mg/dl) 
Fasting           70-110   
PP           80-140   
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Lipid 
profile 
(mg/dl) 
Serum cholesterol         150-200   
HDL           30-60   
 
LDL        Upto 130   
VLDL             40   
TGL       Upto 160   
RFT 
(mg/dl) 
Blood urea          16-50   
Serum creatinine          0.6-1.2   
LFT 
(mg/dl) 
Total bilirubin          0.2-1.2   
Direct bilirubin           0.1-1.2   
Indirect bilirubin           0.2-0.7   
Serum total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
SGOT 
 
0-40  
 
 
 
SGPT            0-35   
Alkaline 
phosphatase         80-290   
Serum Uric acid M: 3-9,W 2.5-7.5 
W: 2.5-7.5 
  
Serum calcium 9-11   
Serum phosphorus 2-5   
 
A.SPECIFIC TESTS 
INVESTIGATION NORMAL VALUES 
BEFORE TMT 
(with date) 
AFTER TMT 
(with date) 
RA factor >10 IU/ml +VE   
ASO titre >200 IU/ml + VE   
CRP >6 mg/l  + VE   
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B.URINE INVESTIGATION: 
Urine investigation Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
Bile salts   
Bile pigments   
C. RADIOLOGICAL EXAMINATIONS 
     X-Ray Affected area- AP view, Lateral view 
 BEFORE TMT AFTER TMT 
XRAY 
CHANGES   
 
 
Date:          
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                              Signature of the HOD 
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    NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM V: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have 
the   right to withdraw from the study at any time without in any way it affecting my 
further medical care”. "I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that 
the individual has given consent freely.”                                                   
 
Date: 
 
 Signature of a witness                                    Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)       
Date:    
Station:                                                                                  
Signature of the Investigator: 
 Signature of the Lecturer:                                                         Signature of the HOD 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¦ºý¨É 
         ¯¾¢ÃÅ¡¾ Í§Ã¡½¢¾õ §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸û «Á¢÷¾Ãº Á¡ò¾¢¨Ã 
(¯û ÁÕóÐ) ÁüÚõ Í§Ã¡½¢¾ Å¡¾ ±ñ¦½ö (¦ÅÇ¢ ÁÕóÐ) ¬¸¢ÂÅüÈ¢ý 
ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø  ÀÊÅõ 
´ôÒ¾ø ÀÊÅõ           
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
    ¿¡ý þó¾ ¬ö× ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌô ÒÃ¢Ôõ 
Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
 §¾¾¢ :                                                     ¨¸¦Â¡ôÀõ : 
 þ¼õ:                                                      ¦ÀÂ÷         : 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
±ýÉ¢¼õ þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ 
ÁÕòÐÅ ÅÆ¢Ó¨È ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ ¸ñ¸¡½¢ì¸×õ, 
«¾¨É À¡Ð¸¡ì¸×õ ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ ÀÃ¢§º¡¾¨É¸û ÀüÈ¢ ¾¢Õô¾¢ 
«Ç¢ìÌõ Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì ÜÈôÀð¼Ð. 
¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø, ±ô¦À¡ØÐ 
§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ ±ý¨É Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â 
¦¾Ã¢ó¾¢Õì¸¢ý§Èý. ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì 
¦¸¡ñÎ ¯¾¢ÃÅ¡¾ Í§Ã¡½¢¾õ §¿¡öì¸¡É «Á¢÷¾Ãº Á¡ò¾¢¨Ã (¯û ÁÕóÐ) 
ÁüÚõ Í§Ã¡½¢¾ Å¡¾ ±ñ¦½ö (¦ÅÇ¢ ÁÕóÐ) ÁÕóÐ¸Ç¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý. 
¨¸¦Â¡ôÀõ :      º¡ðº¢ì¸¡Ã÷  ¨¸¦Â¡ôÀõ   : 
¦ÀÂ÷          :                                     ¦ÀÂ÷           :   
§¾¾¢           :                                                           ¯È×Ó¨È         :                                                              
þ¼õ          :                                                        
Å¢Ã¢×¨ÃÂ¡Ç÷ ¨¸¦Â¡ôÀõ :                         Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ     :
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE-CLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM VI     - WITHDRAWAL FORM 
1. SI NO: ------               2 OP /IP NO: ---------  3. NAME: -----------------------          
4. AGE/GENDER: -------              
5. OCCUPATION: ----------------------------       6. SOCIAL STATUS: -----------     
7.CONTACT NUM: --------------------------           
8. DATE OF TRIAL COMMENCEMENT: ------------------------- 
9. DATE OF WITHDRAWAL FROM TRIAL: ------------------- 
10. REASONS FOR WITHDRAWAL: 
· Long absence at reporting :                          Yes/ No 
· Irregular treatment:                                        Yes/ No 
· Shift of locality :                                             Yes/No 
· Increase in severity of symptoms:                   Yes/No 
· Development of severe adverse drug reactions:   Yes/No 
 
Date:          
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                              Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM VII – PATIENT INFORMATION SHEET 
Name of Principal Investigator : Dr. S Kumar. 
Name of the institute      :  National Institute of Siddha, 
                                        Tambaram Sanatorium, 
                                         Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
       I, Dr. S. Kumar, studying M.D(Siddha) at National Institute of  Siddha, 
Tambaram Sanatorium is doing a trial on Uthiravatha Suronitham ( Rheumatoid 
Arthritis). Rheumatoid arthritis (RA) is a most common persistent inflammatory 
arthritis, occurring throughout the world and in all ethnic groups. In this regard, I am in a 
need to ask you few questions. I will maintain confidentiality of your comments and data 
obtained. There will be no risk of disclosing your identity and no physical, psychological 
or professional risk is involved by taking part in this study. Taking part in this study is 
voluntary. No compensation will be paid to you  for  taking  part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
Amirtharasa Mathirai (Internal medicine -130mg BD with water for 48 days) and 
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Suronitha Vatha Ennai (external medicine) if you wish to stay in the In Patient ward 
Varmam Treatment will be provided to you assuring that you will not be definitely hurt 
in any course of treatment. 
  The information I am collecting in this study will remain between you and the 
principal investigator (myself). I will ask you few questions through a questionnaire. The 
questionnaire will take approximately 20 minutes of your time. 
If you want more information about this study before taking part, you can ask me 
all the questions you want or contact Dr. S. Kumar, PG Scholar cum principal 
investigator of this study, attached to National Institute of Siddha,Chennai-47. You can 
also contact the Member-secretary of Ethics committee, National Institute Siddha, 
Chennai 600047, Tel No : 9003541718, for rights and participation in the study.  
 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
   ¦ºý¨É                                                                       
¯¾¢ÃÅ¡¾ Í§Ã¡½¢¾õ §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý «Á¢÷¾Ãº Á¡ò¾¢¨Ã 
(¯û ÁÕóÐ)  ÁüÚõ Í§Ã¡½¢¾ Å¡¾ ±ñ¦½ö (¦ÅÇ¢ ÁÕóÐ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì  
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷    : ÁÕòÐÅ÷ º.ÌÁ¡÷, 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷     :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, 
                                 ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ, 
                                  ¦ºý¨É 600047. 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý 
ÁÕòÐÅ÷ º.ÌÁ¡÷, ¯¾¢ÃÅ¡¾ Í§Ã¡½¢¾õ ±ýÛõ §¿¡Â¢ø ÁÕòÐÅ ¬Ã¡öîº¢Â¢ø 
®ÎÀðÎû§Çý.               
¯¾¢ÃÅ¡¾ Í§Ã¡½¢¾ §¿¡ö (ãðÎ §¿¡ö) ±ýÛõ §¿¡Â¡ÉÐ º¢ò¾ 
ÁÕòÐÅò¾¢ø º¢Ú, ¦ÀÕ ãðÎ¸Ç¢ø ÅÄ¢,Å£ì¸ò¨¾ ¯ñ¼¡ì¸¢ ¸¡¨ÄÂ¢ø Å¢¨ÈôÒ 
¾ý¨Á¨Â ¯ñ¼¡ìÌõ º¢Ä ºÁÂí¸Ç¢ø º¢Ú ÍÃò¨¾Ôõ ¯ñ¼¡ìÌõ þÐ ÀÃÅì 
ÜÊÂ §¿¡ö «øÄ. 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Çì §¸ð¸×õ, §¾¨ÅÂ¡É 
¬öÅ¸ô ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý. 
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø 
¯ûÁÕó¾¡¸ «Á¢÷¾Ãº Á¡ò¾¢¨Ã 130 Á¢.¸¢ ¾ñ½£Ã¢ø 2 §Å¨Ç (¸¡¨Ä,Á¡¨Ä) 
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¯½×ìÌô À¢ý ´Õ Áñ¼Äõ (48 ¿¡ð¸û) ¯ð¦¸¡ûÇ §ÅñÎõ. ¦ÅÇ¢ ÁÕó¾¡¸ 
Í§Ã¡½¢¾ Å¡¾ ±ñ¦½ö¨Â ¾¼Å §ÅñÎõ. ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 7 ¿¡ð¸ÙìÌ 
´ÕÓ¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. ¯û §¿¡Â¡Ç¢Â¡¸ ¾í¸ Å¢ÕôÀõ 
¦¾Ã¢Å¢ìÌõ Àðºò¾¢ø §¿¡öìÌò ¾Ìó¾ Å÷Áî º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
þó¾ ÁÕóÐ º¢ÈôÀ¡¸ ¯¾¢ÃÅ¡¾ Í§Ã¡½¢¾õ  §¿¡öì¸¡¸ «í¸£¸Ã¢ì¸ôÀð¼ 
º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. 
þó¾ ¬Ã¡öîº¢Â¢ø ¾í¸¨Ç «ÛÁ¾¢ò¾ À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ -
þø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ ¬Ã¡öîº¢Â¢ø þÕóÐ Å¢Ç¸¢ì ¦¸¡ûÇ 
¯Ã¢¨Á ¯ûÇÐ. 
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ ÁüÈ Å¢ÀÃí¸ÙìÌõ 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕòÐÅ÷: º. ÌÁ¡÷ (Àð¼ §Áü ÀÊôÀ¡Ç÷ º¢ÈôÒ 
ÁÕòÐÅ Ð¨È) «Ï¸×õ. ¨¸ô§Àº¢ ±ñ 9500060011 
§ÁÖõ  þó¾ ¬Ã¡öîº¢ìÌ ¾ì¸ «ÛÁ¾¢î º¡ýÚ (IEC) ¦ÀÈôÀðÎûÇÐ. 
þó¾ ÁÕóÐ ÓüÈ¢Öõ À¡Ð¸¡ôÀ¡É ãÄ¢¨¸¸¨Çì ¦¸¡ñÎ ¾Â¡Ã¢ì¸ô 
ÀðÎûÇÐ. Àì¸ Å¢¨Ç×¸¨Ç ²üÀÎò¾¡Ð. 
§ÁÖõ ¯½× Ó¨ÈÂ¢ø ÁÕòÐÅÃ¡ø ÜÈôÀÎõ Àò¾¢Âõ  ¸¡ìÌÁ¡Ú 
«È¢×Úò¾ ÀÎ¸¢ÈÐ. 
þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ 
±É ¯Ú¾¢«Ç¢ì¸¢§Èý. 
þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ò ¦¾¡¨¸Ôõ ÅÆí¸ô À¼ Á¡ð¼¡Ð. 
þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø §¾º¢Â 
º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE-CLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM VIII - DRUG COMPLIANCE FORM 
SERIAL NO:  
OP/IP NO: 
NAME:        
AGE/ GENDER:                                  
DRUG NAME:  Amirtharasa Mathirai (Internal medicine -130 mg BD): 
OPD: 
On 1st     day-Date:    Drugs issued: 130 gms Drugs returned:  gms 
On 8th   day-Date:     Drugs issued: 130 gms Drugs returned:  gms 
On 15th day-Date:         Drugs issued:  130 gms Drugs returned:  gms 
On 22nd day-Date:         Drugs issued: 130 gms Drugs returned:  gms 
On 29th day-Date:          Drugs issued: 130 gms Drugs returned:  gms 
On 36th day-Date:          Drugs issued: 130 gms Drugs returned:  gms 
On 43rd day-Date:          Drugs issued: 130 gms Drugs returned:  gms  
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IPD: 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD 
Day        Date Morning Evening Day       Date Morning Evening 
Day 1    Day 2    
Day 3    Day 4    
Day 5    Day 6    
Day 7    Day 8    
Day 9    Day 10    
Day 11    Day 12    
Day 13    Day 14    
Day 15    Day 16    
Day 17    Day 18    
Day 19    Day 20    
Day 21    Day 22    
Day 23    Day 24    
Day 25    Day 26    
Day 27    Day 28    
Day 29    Day 30    
Day 31    Day 32    
Day 33    Day 34    
Day 35    Day 36    
Day 37    Day 38    
Day 39    Day 40    
Day 41    Day 42    
Day 43    Day 44    
Day 45    Day 46    
Day 47    Day 48    
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM IX - DIETARY ADVICE FORM 
§º÷ì¸ì ÜÊÂ ¯½×¸û (Diet to be included): 
¸¡ö¸û (Vegetables): 
 ¸ò¾Ã¢ôÀ¢ïÍ    (Unripe brinjal) 
 ÓÕí¨¸ôÀ¢ïÍ   (Unripe drumstick) 
 «Å¨ÃôÀ¢ïÍ   (Unripe Dolichos bean) 
¸£¨Ã¸û (Greens): 
 ¦À¡ýÉ¡í¸¡½¢   (Sessile plant [Alternanthera sessilis] ) 
 ãì¸¢Ãð¨¼   (Hog weed [Boerhaavia diffusa] ) 
 àÐ§Å¨Ç           (Climbing brinjal [Solanum trilobatum] ) 
 ÓÕí¨¸ì¸£¨Ã   (Leaves of Drumstick [Moringa oleifera] ) 
      ¸È¢§ÅôÀ¢¨Ä  (Curry leaf [Murraya koenigii] ) 
      Ó¼ì¸Úò¾¡ý   (Winter cherry [Cardiospermum halicacabum] ) 
 «Ú¸£¨Ã    (Amaranthus tristis) 
 ¸Ã¢º¡¨Ä    (trailing eclipta [Eclipta prostrate] ) 
ÀÆí¸û (Fruits):  
     Á¡Ð¨Ç    (Pomegranate) 
     ¬ôÀ¢û    (Apple) 
     ÀôÀ¡Ç¢    (Papaya) 
     ¬ÃïÍ    (Orange) 
     §ÀÃ£î¨º    (Dates) 
              «ò¾¢    (Fig) 
              ¿¡Åø    (Jambul [Syzygium cumini] ) 
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«¨ºÅõ (Non-vegetarian diet): 
  ¦ÅûÇ¡ðÎì¸È¢   (Meat)  
  ¸¡¨¼     (Quail) 
  º¢Ú þÈ¡ø Á£ý   (Prawn) 
¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û (Diet to be avoided):                                            
              Í¨Ã     (Bottle gourd)                              
              âº½¢     (Pumpkin)                             
              ¦ÅûÇÃ¢ì¸¡ö   (Cucumber)             
Ò¼¨Ä     (Snake gourd) 
À£÷ìÌ     (Ridged gourd)    
  ¯ÙóÐ    (Black gram)                                                
¦Á¡î¨º    (Indian butter Bean) 
¸¡Ã¡Á½¢    (Cow gram) 
¦¸¡ûÙ    (Horse gram)                       
¸ÎÌ     (Mustard)                          
±ñ¦½ö    (Gingelly oil)         
ÒÇ¢ôÒ     (Sour)   
¯ôÒ     (Salt)           
Å¡Ôô ¦À¡Õð¸û   (Vatha diet)  
¯Õ¨Çì ¸¢ÆíÌ  (Potato) 
Å¡¨Æì ¸¡ö   (Plantain) 
Ò¨¸Â¢¨Ä    (Tobacco)      
ÁÐ «ÕóÐ¾ø   (Alcohol) 
¦Àñ§À¡¸õ 
 (þîº¡ Àò¾¢Âõ)   [Sexual intercourse] 
ÁÕòÐÅ «È¢×¨Ã (Medical advice): 
· ®ÃÁ¢øÄ¡ò ¾¨ÃÂ¢Öõ, ÀÎì¨¸Â¢Öõ ÀÎò¾ø §ÅñÎõ 
 (Should avoid sleeping in wet floor or mattress) 
· ÌÇ¢÷ ¸¡üÚ ÀÎõÀÊÂ¡É þ¼ò¾¢ø  þÕôÀ¨¾ ¾Å¢÷ì¸×õ  
(Try to avoid cool breeze)  
· ¾¨ÄÂ¨½ ÀÂýÀÎòÐÅ¨¾ ¾Å¢÷ì¸ §ÅñÎõ  
(Should avoid sleeping in Pillow). 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “AMIRTHARASA MATHIRAI 
(INTERNAL MEDICINE) AND SURONITHA VATHA ENNAI (EXTERNAL 
MEDICINE) FOR THE TREATMENT OF UTHIRA VATHA SURONITHAM 
(RHEUMATOID ARTHRITIS)”. 
FORM X - ADVERSE REACTION REPORTING FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                    AGE:                                                 GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:      TIME: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
MANAGEMENT: 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                            Signature of the HOD 
 
